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Tuberculosis (TB) remains a major public health burden. The immunocompetant host
responds to Mycobacterium tuberculosis (MTB) infection by the formation of granulomas,
which initially prevent uncontrolled bacterial proliferation and dissemination. However,
increasing evidence suggests that granuloma formation promotes persistence of the
organism by physically separating infected cells from effector lymphocytes and by inducing
a state of non-replicating persistence in the bacilli, making them resistant to the action of
antibiotics. Additionally, immune-mediated tissue destruction likely facilitates disease
transmission. The granulomatous response is in part due to mycobacterial glycolipid
antigens. Therefore, studies were first undertaken to determine the innate mechanisms of
mycobacterial cord factor trehalose-6’6-dimycolate (TDM) on granuloma formation.
Investigations using knock-out mice suggest that TNF-α is involved in the initiation of the
granulomatous response, complement factor C5a generates granuloma cohesiveness, and IL6 is necessary for maintenance of an established granulomatous responses. Studies were
next performed to determine the ability of lactoferrin to modulate the immune response and
pathology to mycobacterial cord factor. Lactoferrin is an iron-binding glycoprotein with
immunomodulatory properties that decrease tissue damage and promote Th1 responses.
Mice challenged with TDM and treated with lactoferrin had decreased size and numbers of
granulomas at the peak of the granulomatous response, accompanied by increased IL-10 and
TGF-β production. Finally, the ability of lactoferrin to serve as a novel therapeutic for the
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treatment of TB was performed by aerosol challenging mice with MTB and treating them
with lactoferrin added to the drinking water. Mice given tap water had lung log10 CFUs of
7.5 ± 0.3 at week 3 post-infection. Lung CFUs were significantly decreased in mice given
lactoferrin starting the day of infection (6.4 ± 0.7) and mice started therapeutically on
lactoferrin at day 7 after established infection (6.5 ± 0.4). Total lung inflammation in
lactoferrin treated mice was significantly decreased, with fewer areas of macrophages,
increased total lymphocytes, and increased numbers of CD4+ and CD8+ cells. The lungs of
lactoferrin treated mice had increased CD4+ IFN-γ+ cells and IL-17 producing cells on
ELISpot analysis. It is hypothesized that lactoferrin decreases bacterial burden during MTB
infection by early induction of Th1 responses.
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Chapter One
General Introduction

2
Epidemiology of tuberculosis
Tuberculosis (TB) is a major cause of infectious morbidity and mortality. TB
causes approximately 1.8 million deaths annually, making it the leading cause of death
due to bacterial infections worldwide [1]. Additionally, nearly one-third of the world’s
population is latently infected with Mycobacterium tuberculosis (MTB) [1]. Over 95%
of drug-susceptible MTB can be cured with a four drug regimen of isoniazid, rifampin,
pyrazinamide, and ethambutol for two months followed by four additional months of
isoniazid and rifampin [2]. However, it is estimated that only half of TB patients are
effectively treated worldwide [1]. Treatment failure occurs because of noncompliance to
the lengthy drug regimen, individual variation in response to antimicrobials against TB,
and drug resistance [2]. With the exception of the potential role of the fluoroquinolones,
there have been no new anti-TB drugs created since rifampin was introduced in the
1960s [3]. Thus, agents with anti-mycobacterial activity or a beneficial effect when used
in combination with the current anti-TB drugs are desperately needed.
TB infection is transmitted by aerosolization of MTB containing droplet nuclei
produced from an infected person by coughing, sneezing, or forced respiratory activities
[4]. Only about 30% of people exposed to TB bacilli get infected. The risk factors for
infection with TB in the United States include residing in the same household as a
person infected with TB, living in an institutionalized setting with infectious TB cases,
older age, immigration from a country with a high prevalence of TB, and living in an
area with a high incidence of TB such as inner cities. The initial infection is
asymptomatic in most individuals. However, a small percentage of infected persons (2 –
23 %) will develop active TB disease [5]. The risk factors for progression to active TB
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disease are malnutrition, certain gastrointestinal surgeries, young and old age, kidney
disease, HIV infection, cancer, immunosuppressive therapies, and intravenous drug use
[4].
TB remains a public health burden despite the availability of antimicrobial
chemotherapy. The incidence of TB significantly decreased in the United States in the
1800s before the advent of TB antibiotics [6]. The decline in TB incidence is possibly
attributed to better housing and ventilation, improved nutrition, milk pasteurization, and
use of sanatoriums to isolate infectious TB cases. The development of streptomycin,
para-aminosalicylic acid, and isoniazid combination therapy in the mid-20th century
resulted in TB becoming a curable disease [7]. Anti-TB chemotherapy was significantly
improved with the introduction of rifampin in a multi-drug regimen, which resulted in an
even more rapid decline in TB incidence and mortality. TB case number decreased
approximately 6% annually from 1953 to 1985 [8]. However, TB incidence in the
United States and other industrialized countries increased 20% from 1985 to 1992. The
resurgence of TB in developed countries is attributed to the HIV/AIDS epidemic,
transmission of TB in institutionalized settings, a rise in immigration from areas with a
high prevalence of TB, and a lack of funding and infrastructure for TB control programs
[6]. The increase in TB incidence was reversed in 1993, with the number of TB cases in
the United States decreasing by approximately 5-7% per year from 1993-1997.
Multidrug resistant (MDR)-TB emerged with the increase of TB incidence in the
United States [8]. Poor patient adherence to treatment regimens and incorrect or erratic
treatment caused by a number of clinical and social factors contributed to the
development of drug-resistant TB [9]. Thus, new anti-TB agents are needed for
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treatment of MDR-TB and to improve current treatment options to allow for shorter and
more intermittent therapy.

M. tuberculosis induced pathology
The hallmark of MTB pathology in the immunocompetant adult is the caseating
granuloma, which consists of central infected macrophages that may differentiate into
foamy macrophages, epithelioid cells, and Langhan’s giant cells (Figure 1.1A) [10]. The
majority of cells in the granuloma are positive for CD68 and CD4 [11]. A layer of
fibrous surrounds the infected macrophages, which isolates the organism and prevents
bacterial dissemination. The periphery of the granuloma consists of lymphocytes that
are a mixture of CD4+, CD8+, and CD20+ cells [11]. Occasional T-regulatory cells are
observed in the lymphocytic portion of the granuloma [11, 12]. The fibrotic portion of
the granuloma causes physical partitioning of infected cells from effector lymphocytes
that are able to kill infected cells and inhibits the penetration of antibiotics [10].
The majority of granulomas persist for the life of the individual without causing active
TB disease. However, approximately 2 - 23% of infected individuals develop
reactivation of infection [5]. These post-primary (secondary) TB cases cause the
majority of TB disease and nearly all transmission of the bacilli [13]. Post-primary TB
is characterized histologically as a lipid pneumonia, with foamy macrophages in alveoli
and lymphocytes in the alveolar walls and alveoli (Figure 1.1B) [11, 14]. The majority
of lymphocytes in lipid pneumonia are positive for CD8, with relatively fewer CD4+
lymphocytes compared to other tissue manifestations of TB. It is hypothesized
that there is an accumulation of mycobacterial antigens, possibly glycolipids, that

5

A

B

C
Figure 1.1. Tuberculosis induced pathology. A. Typical caseating granuloma of
primary TB consists of central necrosis flanked by foamy and epitheliod
macrophages. Occasional Langhan’s giant cells are noted. The periphery of the
granuloma consists of lymphocytes. B. The lipid pneumonia of early post-primary
TB is characterized by alveoli filled with foamy macrophages. Lymphocytes are
found in the alveoli and alveolar walls. C. Cavitary lesions consist of a wall of
macrophages and necrotic debris. Abundant fibrosis and lymphocytes are noted
surrounding the cavity wall. Welsh KJ, et al. Clin Devel Immuno. 2011 [11].
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initiates tissue necrosis and the formation of cavities.
Cavitary lesions, the hallmark of active TB disease, likely result from abrupt
necrosis of the lipid pneumonia [11, 14]. The wall of the cavity consists of necrotic
tissue and foamy macrophages (Figure 1.1C). Numerous lymphocytes line the wall of
the cavity and consist of CD4+, CD8+, CD20+, as well as numerous T-regulatory cells
[11]. The damage to the lung resulting from TB-induced immunopathology causes a
productive cough, producing infectious aerosols that may infect a new host. Modulation
of the inflammatory pathology will likely facilitate improved response to antimicrobials,
limit transmission of the disease, and decrease morbidity [15].

The immune response to M. tuberculosis
MTB infection is initiated by inhalation of TB bacilli that are deposited in the alveoli,
which become phagocytosed by alveolar macrophages [10]. The macrophages produce
tumor necrosis factor-alpha (TNF-α) and chemokines that recruit systemic monocytes,
forming the nascent granuloma (Figure 1.2). The acquired immune response develops
after migration of dendritic cells to the draining lymph nodes. Dendritic cell production
of IL-12 initiates the development of interferon-gamma (IFN-γ) producing Th1 cells,
while the synthesis of interleukin (IL)-6 and transforming growth factor-beta (TGF-β)
promotes the development of Th17 cells [16]. Th1 and Th17 cell populations migrate to
the lung in response to chemokine gradients. The induction of the specific immune
response correlates with control of MTB infection. This section reviews the
cell types and cytokines essential for immunity to MTB.
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Infected alveolar macrophage
TNF-α & chemokines recruit
systemic uninfected macrophages
to lung

Infected dendritic cells migrate
to draining lymph nodes

IL-12
TGF-β
IL-6

Innate granuloma

Lymphocytes traffic to
lung to form mature
granuloma

T-cell

Figure 1.2. Schematic depicting the major immunologic events leading to
granuloma formation. Infection with MTB initiates with the deposition of bacilli into
the alveoli. MTB are phagocytosed by alveolar macrophages that secrete cytokines such
as TNF-α and chemokines that recruit systemic monocytes to form the nascent
granuloma. The adaptive immune response begins when infected dendritic cells migrate
to the draining lymph nodes of the lung. Dendritic cell production of IL-12 polarizes
naive T-cells to the Th1 phenotype, while TGF-β and IL-6 promote Th17 cells.
Lymphocytes migrate to the lung to form the mature granuloma.
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Macrophages
The first cells to encounter TB bacilli are likely alveolar macrophages [17].
Macrophages phagocytose mycobacteria using mannose receptors, complement
receptors, and scavenger receptors [18-20]. The phagosome in most infections
undergoes maturation processes that result in fusion with lysosomes, inducing organelle
acidification and the activation of lytic enzymes that result in bacterial death. However,
MTB is able to prevent phagolysosomal fusion, giving the organism the ability to
survive within macrophages [21]. The mechanism of MTB inhibition of
phagolysosomal fusion may be due to mycobacterial cell wall products, such as
sulfatides and glycolipids [22, 23].
Macrophages have mechanisms to control proliferation of MTB. Macrophage
activation by IFN-γ, and to a lesser extent by TNF-α, causes inducible nitric oxide
synthetase (iNOS) to produce NO and reactive nitrogen intermediates using arginine as
the substrate [21]. Numerous studies have demonstrated the critical importance of
nitrogen oxides in protection against MTB, both in vitro and in vivo [24, 25].
Furthermore, macrophages play a role in antigen presentation and production of IL-12
that are critical for the generation of the adaptive immune response [26, 27].
While macrophages possess the ability to kill MTB, there is some evidence that
macrophages contribute to the chronic nature of MTB infection. Macrophages in TB
infection may become foam cells, possibly by dysregulation of host lipid metabolism
[17]. It was recently reported that foamy macrophages (FM) positive for the dendritic
cell (DC) marker DEC-205 collect in the alveoli along with CD8+ lymphocytes in both
the alveolar walls and alveoli in humans with early post-primary TB [11]. Ordway et al.
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[28] demonstrated that the FM in mouse granulomas stained positive for DEC-205. The
DEC-205 positive FM in mice had additional markers of DCs such as CD40, CD11c,
and major histocompatibility complex II (MHC II) in addition to high levels of
antiapoptotic markers. The importance of FM expressing DC markers has not been
elucidated. However, DCs infected with MTB can harbor the bacilli for long periods of
time and lack efficient mechanisms for eliminating MTB [29-31]. FM with DC
characteristics may thus provide a favorable environment for the growth of MTB.
Furthermore, FM may suppress the cell-mediated immunity that is necessary to
eliminate MTB. For example, FM produce high amounts of TGF-β that can induce
apoptosis of immune cells [32]. Additionally, FM synthesize high levels of iNOS,
which may cause suppression of T-cells [33]. Therefore, FM may cause local immune
suppression that contributes to inability of the immune system to clear post-primary TB.

Dendritic cells
DCs are another innate immune system cell essential for protection against MTB.
DCs are considered permissive for MTB growth because they harbor the bacilli for
extended periods of time and do not appear to be capable of killing MTB, despite
activation with IFN-γ [29-31]. However, DCs are essential for host defense against
MTB because mice lacking CD11c cells were less able to control MTB growth, possibly
by delayed CD4+ T-cell activation [34].
The major function of DCs is to promote T-cell responses following infection
with MTB [35]. DCs that become infected with MTB or have phagocytosed MTB
antigen become activated and produce IL-12p40, enabling the DC to respond to
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chemokines such as CCL19 and CCL21 that allow the DC to migrate to the draining
lymph nodes [36]. DC production of IL-12 to naive T-cells polarizes T-cells to the Th1
phenotype, which are essential for bacterial control. DCs also synthesize IL-6 and TGFβ that generate Th17 cells that play a number of important roles in the immune response
against MTB [36].

T-cells
Cell mediated immunity is essential for host defense again MTB. This is due to
the fact that MTB is an intracellular organism and thus effector T-cells are needed to
control bacterial growth. Both CD4+ and CD8+ T-cells become activated in the
draining lymph nodes of the lung during week one of infection in the mouse model of
MTB; these cells migrate to the lung between two and four weeks post-challenge [37,
38]. A significant portion of these cells are positive for CD69, suggesting that activated
T-cells are migrating to active sites of infection [21].
CD4+ T-cells are critical to the outcome of MTB infection. CD4+ T-cells
respond to antigen presented on MHC II, which present exogenous antigen that was
processed in phagolysosomes [39]. Studies in mice using knock-out mice, adoptive
transfer, and antibody neutralization of CD4+ cells all demonstrate that CD4+ T-cells
are an absolute requirement for infection control [40-44]. Another example of the
importance of the CD4+ T-cell response can be found in humans with advanced HIV,
who develop disseminated mycobacterial infections when CD4+ T-cells reach low levels
[45]. CD4+ T-cells also promote the development of CD8+ cytotoxic T-cells, which are
also important for control of disease pathology [46]. There are four subtypes of CD4+

11
T-cells that play various roles during MTB infection; these are T-cell helper type 1
(Th1), Th2, Th17, and T-regulatory (Treg) cells.
1. Th1 phenotype. Control of MTB infection is strongly dependent on the
induction of a Th1 immune response. The Th1 response is characterized by populations
of CD4+ T-cells that produce IFN-γ upon activation [47]. Th1 responses are initiated by
innate immune cell production of IL-12 during antigen presentation to naive T-cells.
The importance of IL-12 is demonstrated by IL-12p40 deficient mice that have markedly
increased bacterial burdens and decreased survival time when infected with MTB [48].
The IL-12 induced generation of CD4+ IFN-γ producing cells are critical for the host
defense against MTB. IFN-γ production by Th1 CD4+ cells causes activation of
macrophages, resulting in phagosome acidification and production of reactive nitrogen
species capable of killing MTB [46]. IFN-γ additionally promotes upregulation of MHC
II expression that further induces antigen presentation and T-cell stimulation [39, 49].
The importance of IFN-γ production is highlighted by IFN-γ knock-out mice that are
extremely susceptible to MTB [50, 51]. Additionally, humans with mutations in IFN-γ
or its receptor are likely to have serious mycobacterial infections [52]. Therefore, it is
critical that immunomodulatory agents useful in control of MTB infection produce a
strong Th1 response.
2. Th2 phenotype. Th2 immune responses are characterized by the production of
cytokines such as IL-4 and IL-10. The role of Th2 responses in TB infection is unclear.
The increase in bacterial burden that occurs after 3 weeks in mice challenged with a high
dose of MTB is accompanied by increased IL-4 [53]. Additionally, IL-4 knock-out mice
were more resistant to MTB infection [21]. However, IL-10 deficient mice do not have
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increased resistance in comparison to wild-type mice [54]. Detection of Th2 responses
in humans is difficult [21]. It has been reported in humans that decreased Th1 responses,
but not increased Th2 responses, are found in PBMCs from TB patients [55-57]. Thus,
elevated Th2 responses are not likely associated with TB in humans.
3. Th17 phenotype. While Th1 responses are clearly necessary for host defense
against MTB, this immune response alone is not sufficient [21]. Th17 cells are a
recently discovered T-cell subset with a number of regulatory functions. Th17 responses
are initiated by TGF-β in combination with IL-6, and further expanded by IL-23 [58].
Th17 cells synthesize characteristic cytokines IL-17A, IL-17F, IL-21, and IL-22 that
promote upregulation of other proinflammatory mediators including chemokines, IL-6,
and GM-CSF [59-63]. A number of investigations have demonstrated that Th17 cells
may play an important role in the immune response against MTB [64-66]. Enhancement
of IL-17 responses early in MTB infection by use of an IL-23 synthesizing adenovirus
resulted in reduced lung pathology and decreased bacterial burden [67]. Additionally,
Th17 cells from humans recently infected with TB had the phenotypic markers of longlived central memory cells and were distinct from Th1 effector memory cells [68],
suggesting that Th17 cells may give long-lasting immunity to TB.
4. Treg cells. Treg cells, identified by Foxp3 expression, are considered essential
for preventing autoimmunity [69]. However, the function of Tregs in infectious diseases
including MTB is incompletely understood. Tregs synthesize suppressive cytokines
such as IL-10 and TGF-β that limit excess inflammation, but may prevent clearance of
pathogens [70]. Treg cells in the peripheral blood decrease in newly infected contacts of
patients with active TB disease, possibly due to their migration to the infected lung [71].
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Tregs accumulate in sites of disease and in blood as the infection progresses [12, 72-74].
Differential Foxp3 expression in PBMCs differentiated active TB from latent TB
infection [75]. Foxp3+ cells were found to decrease T-cell responses to mycobacterial
antigens in human patients [76]. Neutralization of Treg cells during mouse models of
infection enhanced elimination of MTB [77, 78], providing further support that Treg
cells have a negative impact on MTB infection. Another investigation showed that small
numbers of Tregs specific for MTB prevent the aggregation of CD4+ and CD8+ T-cells
in infected mouse lungs [79]. Finally, it was recently shown that human cavitary lesions,
lesions that rarely spontaneously heal, contained a higher percentage of Tregs compared
to other pathological manifestations of TB [11].
CD8 T-cells. CD8+ T-cells also potentially play a role in MTB infection. These
cells recognize antigen presented on MHC I molecules, and may produce IFN-γ when
activated. MTB antigens are thought to gain access to the MHC I molecules by pores in
the vesicular membrane of the phagosome or an alternate processing pathway for MHC I
[80]. CD8+ lymphocytes can be found in granulomas at approximately the same
frequency as CD4+ cells [11]. CD8+ T-cells may directly lyse MTB-infected cells, and
have been reported to potentially overcome the absence of CD4+ T-cells [43, 81, 82].
The mechanisms of CD8+ cell dependent lysis are perforin and granulysin [83-85].
However, mice lacking CD8+ T-cells have higher bacterial burdens, but generate normal
granulomas and ultimately control the infection [86].

Soluble factors
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A number of protein mediators such as the complement system and cytokines
play essential roles in during bacterial infections. Cytokines function as signaling
mediators between cells and are essential regulators of all aspects of immunity. The
cytokines central to the adaptive immune response have been discussed elsewhere in this
review. This section will discuss the functions of the complement system and the
cytokines TNF-α and IL-6.
The complement system. The complement system plays a central role in innate
immunity and the initiation of adaptive immunity [87]. The three major pathways of
complement are the classical, alternative, and lectin pathways. The classical pathway
begins when certain subclasses of IgG or IgM bind to antigen. C1q binding to Fc sites
induces C1r to activate C1s. C1s cleaves C4 and C2, which forms the classical pathway
C3 convertase (C4b2a). The classical C3 convertase cleaves C3, generating the C5
convertase (C4b2a3b) that cleaves C5. The result may be lysis of cells by the deposition
of C5b-9 on the surface of cells, inflammation by C3a and C5a-induced chemotaxis of
leukocytes, or opsonization and phagocytosis of cells mediated by C3b. The lectin
pathway is similar to the classical pathway, except that it starts with the binding of
mannose-binding lectin to microbial surfaces that induces proteases to cleave C4 and C2.
The alternate pathway is initiated when C3 undergoes spontaneous auto-cleavage to
C3b. C3b binds to factor B and properdin to form the C3 convertase (C3bBb). The C3
convertase enzymatically cleaves additional C3 to form the C5 convertase (C3bBbC3b),
which cleaves C5 [87].
New evidence suggests that complement plays a major role in the induction of Tcell responses in addition to its clear role in innate and humoral immunity [88]. The
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binding of complement factors to the C3a and C5a receptors promotes the migration of
antigen presenting cells to areas of infection, where they present antigen to T-cells and
modulate IL-12 production [89-91]. Binding of immune complexes to the C1q receptor
on T-cells promotes T-cell activation with production of TNF-α and IFN-γ [92]. C5a
binding to the C5a receptor on T-cells directs their migration to sites of inflammation
[93]. Both CD4+ and CD8+ T-cells responses in C3 deficient mice are decreased in
viral infection models [94-96]. The precise role of complement factors in immunity and
pathology during MTB infection is unclear. It was reported that mice deficient in
complement C5 have decreased survival, increased inflammation, and decreased
macrophage cytokine production [97, 98]. The studies presented here examine the role
of C5a in the early initiation and maintenance of the granulomatous response.
TNF-α. TNF-α is a proinflammatory cytokine synthesized by dendritic cells,
macrophages, and T-cells that plays a critical role in the regulation of acute and chronic
granulomas [99]. Neutralization of TNF-α or mice with a deficiency of TNF-α or its
receptor rapidly succumb to MTB infection, have markedly increased bacterial loads,
and a dysregulated granulomatous response [100-102]. The mechanism of TNF-α in
host resistance to MTB is possibly due to its ability to partially activate macrophages,
increasing their cytotoxicity, and facilitating the interactions between macrophages and
T-cells that are necessary to generate granulomas [103].
However, there is increasing evidence that the granulomatous response promotes
a survival advantage to MTB in the host and that the organism possesses specific
mechanisms to drive TNF-α production [15]. Mycobacterial cell walls contain
glycolipids, such as trehalose dimycolate, that induce TNF-α and drive granuloma
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formation [99]. MTB may also promote TNF-α production by direct interference with
intracellular signaling. A MTB mutant deficient in the adenylate cyclase Rv0386 was
characterized by reduced cAMP after infection, accompanied by decreased protein
kinase A and CREB activation, and ultimately decreased TNF-α synthesis by infected
macrophages [104]. The mutant MTB had poor survival in a mouse infection model and
decreased lung pathology. It has thus been proposed that the induction of excessive
TNF-α production by MTB is a component of the virulence of the organism [15].
IL-6. The role of IL-6 in the host defense against MTB is unclear. This cytokine
is produced by fibroblasts, macrophages, B-cells, and T-cells. IL-6 possibly interferes
with IFN-γ signaling and increases IL-4 production, both of which may inhibit protective
Th1 responses [105]. Production of IL-6 by BCG infected macrophages inhibited T-cell
responses [106]. However, IL-6 -/- mice infected with MTB have produced mixed
results. Intravenous challenge MTB was lethal for IL-6 knock-out mice [107]; however,
aerosol challenge of the IL-6 -/- mice had later production of IFN-γ but were ultimately
able to control the infection [105]. Thus, IL-6 may play a role in the immune response
against MTB, but its precise function remains to be determined.

The role of trehalose 6,6’-dimycolate on MTB pathogenesis
Mycobacterial cell walls possess abundant lipid, accounting for approximately
half of the dry weight of MTB [108]. The lipid content of MTB includes mycolic acids,
which consist of long chains of fatty acids with 78 – 90 carbons [109]. Trehalose 6,6’dimycolate (TDM) is the most abundant glycolipid on the surface of MTB [13]. TDM,
also referred to as mycobacterial cord factor, was identified due to the ability of MTB to
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form serpentine cords. TDM structurally consists of two trehalose molecules, each with
a mycolic acid chain with 60 – 90 carbons (Figure 1.3) [13]. The biologic activity of
TDM depends on its presentation [110]. TDM mixed in an aqueous solution forms
micelles that are non-toxic; TDM on the surface of MTB is hypothesized to exist in the
micelle form. In contrast, TDM monolayers formed on hydrophobic surfaces, such as
oil-water interfaces, are toxic in microgram quantities [110]. TDM is thought to play a
number of important roles in MTB pathogenesis, including virulence and granuloma
formation.
TDM is hypothesized to contribute to the virulence of MTB. Higher levels of
TDM are found on the surface of virulent MTB than avirulent organisms [111].
Extraction of TDM from mycobacteria decreases the organism’s ability to survive in
both macrophages and mice; reconstituting purified TDM largely restores the organisms’
survival in macrophages [112-114]. Decreased MTB ability to produce excess TDM is
accompanied by a decrease in virulence [115, 116]. Furthermore, alterations in the
structure of TDM such as absence of the cyclopropane rings results in decreased
bacterial growth in macrophages and mice [117]. Removal of TDM from the surface of
MTB resulted in enhanced macrophage ability to undergo phagosome acidification and
fusion with lysosomes [112]. Additionally, surface TDM decreases macrophage
expression of MHC II, CD40, CD80, CD86, and CD1d, markers that are essential for
antigen presentation and stimulation of T-cells [23].
TDM is likely involved in induction of the granulomatous response during MTB
infection. Administration of a single dose of TDM in emulsion form induces foreign
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Figure 1.3. Structure of trehalose-6,6’-dimycolate (TDM). TDM is
composed to two molecules of trehalose each with a mycolate attached. The
structure contains double bonds and cyclopropane molecules that are
necessary for its activity [123].
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body lung granulomas; these granulomas peak in size and number at one week and
completely resolve two-weeks post-challenge [80]. This granulomatous response is
accompanied by pro-inflammatory cytokine production including TNF-α, IL-6, IL-1β,
IFN-γ, IL-12, as well as chemokines [118, 119]. TDM can additionally promote
hypersensitive granulomatous response by TDM challenging mice that have been
immunized with TDM and protein [80, 120, 121]. Hypersensitive granulomas in
response to TDM are characterized by large, destructive granulomas that have a
significant lymphocyte composition. The hypersensitive response is accompanied by
synthesis of Th1 cytokines such as IFN-γ and IL-2. The hypersensitive granulomatous
response was demonstrated to be transferable by CD3+ TDM immunized cells; CD4+
cells were later determined to be responsible [120, 121]. TDM has also been implicated
in the induction of caseating granulomas [110].
It has long been established that the proinflammatory responses to TDM are
mediated by macrophages [122]. However, receptors for binding and signaling for TDM
were only recently discovered. Bowdish et al [122] reported that the macrophage
scavenger receptor MARCO forms a complex with TLR2 and CD14 that recognizes
TDM-coated microspheres. Other investigators showed that macrophage inducible Ctype lectin (Mincle) bound TDM coated onto plates [123, 124]. Mincle response to
TDM requires the Fc receptor γ chain (FcRγ) and Sky-Card9-Bcl10-Malt1 signaling
pathway [125].
Glycolipid-specific T-cells are induced in mycobacterial infected humans and
guinea pigs [126]. However, antigen presentation occurs via CD1 rather than MHC I or
II. CD1 molecules present hydrophobic ligands [80]. Humans possess five CD1 family

20
members, divided into group 1 (CD1a, CD1b, CD1c) and group 2 (CD1d, CD1e). Mice,
however, have only two CD1 genes (CD1d1 and CD1d2) [80]. Therefore, it is difficult
to compare studies of humans and mice on CD1 presentation of glycolipids. Murine
macrophages upregulate CD1d1 after stimulation with TDM [127], but TDM-specific
CD1d T-cells have not been identified in mice. However, it was demonstrated that mice
lacking CD1d (CD1d -/-) have dysregulated acute granulomatous response to TDM
[128]. In the hypersensitive granuloma model, CD1d -/- mice had less destructive lung
lesions, loosely organized CD3+ lymphocytes, and increased proinflammatory cytokines
[129]. Thus, the precise role of CD1 in the presentation of TDM is still being delineated.
It is well established that TDM induces a number of immunological mediators;
however, the specific cytokines that necessary for granuloma formation are unknown.
Studies from our laboratory demonstrated that regulation of corticosterone in the lung by
11beta-hydroxysteroid dehydrogenases modulates the progression TDM-induced
granuloma formation [130]. The work in this thesis explores the role of complement
factor C5a, TNF-α, and IL-6 in the initiation and maintenance of TDM-induced
granuloma, and the ability of lactoferrin to modulate this granulomatous response.

Modulation of TB-induced immunopathology as an adjuvant to antimicrobial
chemotherapy
Granuloma formation is considered a favorable response that prevents bacterial
replication and dissemination to other organ systems. However, MTB localized within
granulomas are protected from sterilizing antimicrobials and immune-mediated killing
[15]. MTB within granulomas undergo conversion to a state of non-replicating
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persistence that includes changes in biosynthetic pathways and decreased replication
[131, 132]. The action of antibiotics requires bacilli that are actively replicating for
effectiveness and thus are unable to eliminate the dormant MTB within granulomas.
Additionally, reduction of lung inflammatory pathology may facilitate antibiotic
penetration into infected tissue, thereby inducing a faster response to antibiotics [15,
133]. Indeed, MTB mutants that lack the ability to induce granulomas have significantly
reduced survival in mice and less lung pathology [104]. Additionally, it is hypothesized
that the inflammatory response to MTB is responsible for disease transmission;
modulation of the immune response may limit dissemination of the bacilli to new hosts
[15, 17, 134].
Immunomodulators combined with TB antibiotics has generated favorable results
in human clinical studies. One clinical trial combined etanercept, a soluble TNF-α
receptor, with standard TB chemotherapy in HIV patients with TB and reported
significantly increased bacterial clearance and improved chest x-ray results in the
patients treated with the combination therapy [135]. Another study explored high-dose
corticosteroids with anti-TB drugs in patients co-infected with HIV and TB [136].
Sputum culture conversion was significantly increased in the patients given prednisolone
compared to patients given standard TB chemotherapy alone. The studies in this thesis
use lactoferrin as an immunomodulator during MTB infection; lactoferrin has numerous
advantages over other available immunomodulators because it does not suppress the
immune system and has a proven safety record in a number of animal studies and human
clinical trials [137-139].
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Lactoferrin as an immune modulator
New evidence identifies lactoferrin as an immune response modulator to a
number of infectious and inflammatory stimuli [140, 141]. Lactoferrin is member of the
transferrin family and is found in epithelial secretions as well as in the granules of
neutrophils [140]. The serum concentration of lactoferrin is normally low, at less than 1
µg/ml, but markedly increases during injury and inflammation [142, 143]. Lactoferrin
receptors are found on many different immune cells, such as macrophages, dendritic
cells, and T-cells [144-146]. Reported immunomodulatory properties of lactoferrin
include macrophage activation, promoting polymorphonuclear cell phagocytosis,
enhancement of T- and B-cell maturation, and augmentation of antigen specific immune
responses [147-149].

Lactoferrin modulation of innate immunity
Lactoferrin modulates the activity of innate antigen presenting cells (APCs), which
in turn have the potential to alter T-cell responses. APCs, including dendritic cells,
process and present antigen to naive CD4+ T-cells using MHC II along with costimulatory molecules such as CD40, CD80, and CD86 [39, 150]. APC production of
IL-12 promotes the development of naive CD4+ T-cells to a Th1 phenotype [26, 151].
Thus, alteration of APC cytokine production and surface molecule expression has the
potential to enhance the development of the acquired immune response.
Lactoferrin enhances dendritic cell and macrophage function as APCs to activate
CD4+ T-cells. Macrophages stimulated with IFN-γ and infected with mycobacteria have
decreased MHC II expression [152-154]. Lactoferrin added to activated macrophages
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infected with BCG significantly increased expression of MHC II [155, 156]. Lactoferrin
increased the CD86:CD80 ratio in dendritic cells and macrophages infected with BCG
[155, 157], suggesting that APCs treated with lactoferrin are better at promoting
activation of T-cells during antigen presentation [158, 159]. Indeed, dendritic cells and
macrophages infected with BCG and incubated with lactoferrin had significantly
enhanced IFN-γ production from both CD3+ and CD4+ cells in comparison to APCs
cultured in the absence of lactoferrin [155, 157]. Additionally, lactoferrin increased
expression of CD40 on the mouse macrophage cell line RAW 264.7 as well as peritoneal
macrophages [160]. Immature human dendritic cells cultured with recombinant human
lactoferrin increased human leukocyte antigen II, CD80, CD86, CD83, in addition to
chemokine receptors necessary for migration to draining lymph nodes [161].
IL-12 is essential for the promotion of the Th1 cytokine IFN-γ, both in the
maturation of naive T-cells to the Th1 phenotype and in maximizing production of IFN-γ
from established Th1 effector and memory cells [162, 163]. Injection of lactoferrin
intraperitoneally into mice increased production of IL-12 from peritoneal macrophages
recovered from the mice [147]. Other investigators have shown that lactoferrin
administered orally increases IL-12p40 expression, accompanied by decreased
expression of IL-10 [164]. Indeed, macrophages infected with BCG and treated with
lactoferrin demonstrated a significantly increased ratio of IL-12 to IL-10, a cytokine that
inhibits the action of IL-12 [147]. Furthermore, lactoferrin increased TGF-β production
from dendritic cells and macrophages infected with BCG [155, 157]. TGF-β in
combination with IL-6 promotes the generation of Th17 responses [59], which may play
an important role in protection against MTB [64, 68]. In summary, these studies indicate
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that lactoferrin strongly modulates APC function. The impact of lactoferrin on innate
cell function involved in the initial interaction with microbes gives it potential to
enhance the generation of the adaptive immune response, with clear mechanisms to
support its use as an adjunct therapeutic for the treatment of TB.

Lactoferrin modulation of the acquired immune response
Lactoferrin has a number of direct effects on T-cell responses in addition to
modulation of innate responses. CD4+ and CD8+ T-cells possess receptors for
lactoferrin [165]. Lactoferrin affects the levels of co-stimulatory surface molecules that
impact T-cell function, suggesting that lactoferrin modulates T-cell response to antigen.
The maturation of double negative mouse T-cells preferentially towards CD4+ T-cells is
enhanced by human lactoferrin, possibly through Erk2 and p56lck to activate the MAP
kinase pathway [166, 167]. Administration of oral lactoferrin to mice increased CD4+
and γδ T-cells as well as total circulating granulocytes [164]. Lactoferrin increased
expression of leukocyte function associated antigen, an adhesion molecule involved in
cell-to-cell contact on T-cells [168]. Expression of the human T-cell ζ-chain, a
component of the CD3 T-cell receptor complex involved in signaling, was enhanced by
lactoferrin [169].
Lactoferrin can polarize naive T-cells to either Th1 or Th2 phenotypes, depending on
the cytokine environment and antigen. Studies demonstrate that lactoferrin can augment
production of cytokines needed for the development of a Th1 response, with increase of
the delayed-type hypersensitivity (DTH) response to BCG, sheep red blood cells, and
ovalbumin [147, 170, 171]. Transgenic mice expressing human lactoferrin and infected
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with Staphylococcus aureus had increased IFN-γ and TNF-α, along with decreased IL10 and IL-5 [172]. Oral administration of lactoferrin increased Th1 T-cell responses,
indicated by enhanced levels of IFN-γ, in both naive and tumor-harboring mice [173,
174]. The IL-12:IL-10 ratio was increased by lactoferrin in LPS stimulated splenocytes
[175]. Furthermore, chronic hepatitis C virus elimination was augmented by the
combination of lactoferrin and interferon therapy, possibly by increasing Th1 responses
[176]. In contrast, lactoferrin increased IL-10 and decreased IFN-γ in an infection model
of Toxoplasma gondii, indicating the enhancement of Th2 responses [177]. The effects
of lactoferrin on Th17 cells are currently unknown.
Lactoferrin additionally alters B-cell responses. Immature B-cell incubation with
lactoferrin increased their proliferation in response to antigen-specific T-cells [149].
Lactoferrin augments maturation of immature mouse B-cells, indicated by increased
expression of the complement 3 receptor and IgD [149]. Lactoferrin increases mouse
Peyer’s patches production of IgG and IgA [178]. Mice treated with lactoferrin had
increased levels of IgG in both the serum and intestine [179]. Additionally, lactoferrin
increases antibody-forming cells and humoral responses to sheep red blood cells in mice
treated with methotrexate and cyclophosphamide [180-182]. Taken together, these
investigations suggest that lactoferrin directly affects B-cells, and enhances their
function as APCs to generate T-cell responses.
Essential for the studies performed here, lactoferrin decreases immune-mediated
tissue damage. For example, mice administered lactoferrin had decreased mortality and
reduced destruction of gut tissue following LPS injection [183]. Lactoferrin also
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decreased tissue damage in mouse models of rheumatoid arthritis and inflammatory
bowel disease [184-186].

Summary of Thesis
This thesis will explore the cytokine mechanisms of TDM-induced granulomas
and the ability of lactoferrin to modulate TB-induced immunopathology. Initial studies
examined the role of TNF-α, complement factor C5a, and IL-6 in the initiation and
maintenance of TDM-induced granulomas (Chapter 2). Studies were next undertaken to
explore the ability of lactoferrin to modulate immune-induced pathology to
mycobacterial antigen (Chapter 3). Finally, the ability of lactoferrin to serve as an
adjuvant therapeutic for TB was evaluated by treating MTB infected mice orally with
lactoferrin (Chapter 4). The mechanisms of lactoferrin-mediated immune modulation
during MTB infection are discussed.
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Chapter Two
The role of TNF-α, complement C5a, and IL-6 in the induction and maintenance of
mycobacterial cord factor trehalose 6,6’-dimycolate induced granulomas
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This work was published in the journal Microbiology, 2008 154:1813-24 [119]
Introduction
Mycobacteria are responsible for a number of infectious pathologies that are a
significant global health problem. Disease caused by Mycobacterium tuberculosis
(MTB) results in approximately 2 million deaths annually [1]. Infection usually presents
as pulmonary pathology, characterized by the generation of granulomas that prevent
bacterial dissemination. However, extrapulmonary disease also occurs in which any
organ can become infected including the bones, kidneys, central nervous system, and
gastrointestinal tract [187]. The cytokine mechanisms that induce granuloma formation
have not been fully elucidated. Due to the increasing number of drugs developed to
target cytokines in the therapy of immune-mediated disorders, it is essential to determine
the role these mediators play in the formation and maintenance of mycobacterial induced
granulomas.
Tumor necrosis factor-α (TNF-α) is the major cytokine necessary for the
generation and maintenance of MTB induced granulomas [188]. TNF-α has a number of
immunologic functions that include activation of endothelial cells, initiation of
apoptosis, and proliferation of thymocytes [189]. Antibody neutralization of TNF
prevented control of infection with bacillus Calmette-Guérin (BCG) and granuloma
formation in mice [190]. Mice deficient in the TNF receptor and wild-type mice
administered a TNF-α neutralizing antibody rapidly succumb to infection with MTB
[101]. Additionally, mice lacking TNF do not generate granulomas during
mycobacterial infection, accompanied by delayed recruitment of CD11b+ cells and
production of C-C and C-X-C chemokines [191]. TNF is also essential for long term
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control of persistent infections, with elimination resulting in inability to maintain
granulomas [192].
Complement C5 is another potentially important mediator in the granulomatous
response. Its split product, C5a, recruits cells to sites of inflammation and promotes the
synthesis of cytokine subsets, such as TNF-α, IL-6, and IL-12 [193]. A/J mice, which
lack complement C5, have increased mortality accompanied by markedly increased
inflammatory responses and do not form granulomas in a mouse model of MTB
infection [97]. The complement deficient A/J mice had significantly earlier reactivation
of latent infection, exacerbated responses in an induced chronic infection, and reduced
macrophages synthesis of cytokines and chemokines in comparison to complementsufficient mice [98]. A study by Borders and colleagues [194] showed that mice
deficient in the C5a receptor had exacerbated inflammatory responses with absence of
granulomas. Thus, complement C5 is likely involved in the early initiation of the
granulomatous response, possibly due to recruitment of cells that produce regulating
proinflammatory cytokines to the site of inflammation.
Interleukin-6 (IL-6) is a proinflammatory mediator synthesized by fibroblasts,
macrophages, B-cells, and T-cells that possibly plays a role in mycobacterial infections
by its involvement in acute phase protein and immunoglobulin production, and adaptive
cell activation [195]. In vitro studies possibly indicate a pathologic role for IL-6 in MTB
infection, but these experiments need further clarification. IL-6 synthesis by
macrophages infected with mycobacteria decreases T-cell responses [106] in addition to
decreasing transcriptional activation of interferon- γ (IFN- γ) in uninfected, nearby
macrophages [196]. In vivo studies have generated mixed results. One study found that
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MTB infection was lethal for mice lacking IL-6 [107]; however, another investigation
using IL-6 -/- mice reported that the deficient mice were still able to control the infection
despite delayed synthesis of IFN-γ [105]. Thus, IL-6 likely plays a role in the immune
response to MTB, but its precise function is unclear.
Trehalose-6,6’-dimycolate (TDM) is a glycolipid found on the mycobacterial cell
wall. Purified TDM causes lung pathology in mice that mimics some aspects of MTB
infection, such as granuloma formation and induction of proinflammatory cytokines
[197, 198]. TDM plays a number of important roles in the pathogenesis of MTB
infection, including the induction of caseating granulomas [13, 110, 199]. The TDM
model system may thus be a useful tool to explore the factors necessary for the early
granulomatous response. The precise roles for TNF-α, C5a, and IL-6 in initiation and
maintenance of the granulomatous response to isolated TDM are unknown; thus,
experiments were conducted to explore the responses of mice lacking these critical
immune factors.

Materials and Methods
Animals. Three-to-five week-old, wild-type, female C57BL/6 mice and mice
lacking TNF-α (B6;129S6-Tnftm1Gkl/J), C5a (B10.D2-Hc0H2dH2-T18c/oSnJ), or IL-6
(B6.129S2-Il6tm1Kopf/J) were purchased from the Jackson Laboratories (Bar Harbor,
ME). Animal experiments were performed under the approval of the UTHSC animal
ethics committee (AWP 04-065). Four to six mice per group per indicated time points
were used.
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Preparation of bone marrow-derived macrophages, stimulation with TDM-coated
microspheres, and MTB infection. Bone marrow-derived macrophages from wild-type
C57BL/6 and complement factor C5a deficient (A/J) mice were generated by previously
described methods [200]. Briefly, femurs were flushed with McCoy’s media (Sigma, St.
Louis, MO), and 2 x 106 cells were added to 24 well tissue culture plates (Corning
Incorporated, Corning, NY). Cells were cultured in McCoy’s media (Sigma)
supplemented with 10% fetal bovine serum (FBS) (Sigma), 100 µg ml-1 gentamycin
(Sigma), 100 U ml-1 penicillin (Sigma), and 10 ng ml-1 recombinant murine
granulocyte/macrophage colony stimulating factor (GM-CSF; Chemicon, Billerica,
MA). The cells were cultured at 37 °C in 5% CO2 for seven days, with two media
changes containing GM-CSF. Finally, cells were washed and suspended in Dulbecco’s
modified eagle’s medium (DMEM; Sigma) supplemented with 10% FBS.
TDM-coated and BSA-coated microspheres were generated by previously
described methods [112], and were a generous gift from C. Kan. The microspheres were
added to the bone marrow-derived macrophages at a ratio of 10 beads per cell. IL-6 and
TNF-α protein production was determined in the cell supernatants after a 72 hour
incubation using an ELISA (see below).
MTB Erdman (ATCC 35801) was grown to log phase in Dubos broth (Difco,
Franklin Lakes, NJ) with 7.5% dextrose and 5% BSA as supplements. Petroleum ether
(Sigma) was use to extract mycobacterial surface lipids to generate delipidated MTB, as
previously detailed [112, 114]. The bacteria were vortexed after adding petroleum ether
for 2 minutes, after which they were incubated for 5 minutes at room temperature. The
bacteria were then centrifuged for 10 minutes at 500 g. After removing the supernatants,
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the extraction process was repeated two additional times followed by suspending the
culture in phosphate buffered saline (PBS). Lipid extraction by petroleum ether does not
alter the acid fastness of organisms or viability [112, 114]. Delipidated MTB were
reconstituted by adding 0.01% (50 µg ml-1) purified TDM (Sigma) in petroleum ether
[112, 114]. The bacteria were resuspended in PBS after evaporation of the ether.
Preparation of TDM, tissue processing, and histopathology. A TDM oil-in-water
emulsion was prepared by previously detailed methods [118], with minor modifications
discussed below. Mice were intravenously injected with 50 µL of emulsion, generated
by dissolving 25 µg of purified TDM (Sigma) in 9:1 hexane/ethanol, after which the
solvent was evaporated. One µL of Drakeol (Penreco, Dickinson, TX) was
homogenized into the TDM. Finally, 48 µL of 0.2% Tween 80 (Mallinckrodt,
Hazelwood, MO) in PBS was admixed. Mice were sacrificed by cervical dislocation at
days 0, 4, 7, and 14 after TDM challenge. Lung tissue was aseptically removed,
weighed, and prepared for analysis of cytokines or fixed in 10% formalin for histology.
The lung weight index (LWI) was calculated as an indicator of inflammation intensity
[129, 194, 201] using the following formula:

Lung tissue (approximately 30 mg) was homogenized and put into 2 mL DMEM
(Sigma) supplemented with 10% FBS, 0.01% L-Arginine (Sigma), 0.01% HEPES
(Sigma), 50 µg/mL gentamycin (Sigma) and 100 µg/mL penicillin (Sigma). Samples
were cultured for 4 hours at 37 °C with 5% CO2. The supernatants were kept at -20 °C
until analysis by enzyme-linked immunoassay (ELISA). For histopathologic studies, the
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left lung was placed in 10% formalin, sectioned (5 µm thick), and stained with
hematoxylin and eosin (H & E) per standard methodologies. The remainder of the lung
was frozen in RNA-Bee (TelTest, Inc., Friendswood, TX) and stored at -80 °C for RNA
studies. No significant differences were observed in histopathology or lung weight in
mice given emulsion alone, as previously described [129].
ELISA analysis for lung cytokine and chemokine protein. Levels of interleukin1β (IL-1β), IL-6, interleukin-10 (IL-10), TNF-α, interleukin-12p40 (IL-12p40), IFN-γ,
and macrophage inflammatory protein-1α (MIP-1α) in lung homogenates were analyzed
by a sandwich ELISA as per the manufacturer’s instructions (R&D Systems,
Minneapolis, MN). Briefly, capture antibody was coated on to Costar 96-well plates
followed by washing (0.5% Tween-20 in PBS) and blocking (1% BSA, 5% sucrose,
0.05% NaN3 in PBS). Lung homogenates were incubated at room temperature for 2
hours, after which biotin-conjugated secondary antibodies were used for detection with
visualization by streptavidin-horseradish peroxidase (R&D) and TMB Microwell
Peroxidase Substrate (KPL, Gaithersburg, MD). The reactions were stopped with 2 N
H2SO4. The absorbance was read at 570 nm and 450 nm using an ELISA plate reader
(Molecular Devices, Menlo Park, CA). The average of duplicate wells was generated
using on a standard curve made for each assay with recombinant molecules supplied by
the manufacturer (R&D). The lower limit of detection was 15 - 32 pg/mL.
Extraction of mRNA, reverse transcription, and real-time PCR. Sectioned lung
tissue was minced in 1 ml of RNA-Bee, and RNA extracted using previously detailed
methods [120]. cDNA was generated from 2 µg RNA in First Strand buffer (250 mM
Tris-HCL, pH 8.3, 375 mM KCl, 15 mM MgCl2) (Invitrogen, Carlsbad, CA), with 2.5
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mM deoxynucleotides-triphosphate (dNTPs) (Invitrogen), 0.1 M dithiothreitol (DTT)
(Invitrogen), 20 U RNase inhibitor (Promega, Madison, WI), and 80 U random hexamer
oligonucleotides (Roche Diagnostics GmbH, Mannheim, Germany). 200 U of
SuperScript II reverse transcriptase (Invitrogen) was admixed after heating the reaction
mixture to 70 °C for 5 minutes, followed by incubation at 42 °C for 50 minutes; the
reactions were halted by heating to 70 °C for 15 minutes. The samples were diluted 1:8
with distilled water.
cDNA was quantified with the Taqman assay using fluorogenic probes with
FAM (6-carboxifluorescein) reporter and BHQ-1 (black hole quencher) quencher
(Biosearch, Novato, CA). The primer and probe sequences are shown in Table 2.1. The
reaction mixture contained 1X PCR Buffer (20 mM Tris-HCL pH 8.0, 100 mM KCl, 0.1
mM EDTA, 1 mM DTT, 50% glycerol, 0.5% Tween 20, 0.5% Igepal CA-630) (5 Prime,
Gaithersburg, MD), 200 nM dNTPs (Invitrogen), 1X ROX Reference Dye (Invitrogen),
400 nM of each primer (Integrated DNA Technologies, Coralville, IA), 100 nM probe,
and 1 U/45 µL Taq DNA Polymerase (5 Prime). The ABI Prism 7700 Sequence
Detection System (Applied Biosystems, Foster City, CA) was used for amplification.
The reaction cycle consisted of 95 °C for one minute, followed by 40 cycles of a 12
second step at 95 °C and a one minute step at 60 °C. Data were analyzed by the -2ΔΔCT
method using β-actin message as the calibrator [202].
Statistics. The data are shown as the mean ± one standard deviation. Two way
ANOVA was used to determine differences between groups. A p-value <0.05 was
considered significant.
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Protein

Primers
Sa 5' TCTGGCTCCTAGCACCATGA
AS 5' CCACCGATCCACACAGAGTACT
S
5' CTCATTGTGGCTGTGGAGAA
AS 5' GGTGCTCATGTCCTCATCCT
IL-6
S
5' CCCAATTTCCAATGCTCTC
AS 5' TGAATTGGATGGTCTTGGTC
S
5' CCGATGGGTTGTACCTTGTCT
AS 5' TGGGTGAGGAGCACGTAGTC
S
5' ACTAAGAGAAACCGGCAGAT
AS 5' TTCAGTTCCAGGTCAGTGAT
S
5' AGCAACAGCAAGGCGAAA
AS 5' CTGGACCTGTGGGTTGTTGA
IL-12p40
S
5' AAGTGTGAAGCACCAAATTACTC
AS 5' TTCAAGTCCATGTTTCTTTGC
IL-4
S
5' ATCGGCATTTTGAACGAGGT
AS 5' GACGTTTGGCACATCCATCT
IL-10
S
5' CAGCCGGGAAGACAATAACTG
AS 5' CCGCAGCTCTAGGAGCATG
S
5' CACTGGAGTTGTACGGCAGTG
AS 5' AGAGCAGTGAGCGCTGAATC
IL-17
S
5' GCTCCAGAAGGCCCTCAGA
AS 5' CTTTCCCTCCGCATTGACA
a
S, sense; AS, antisense

Table 2.1. Oligonucleotide primers and probes.

Probes
5' ATCAAGATCATTGCTCCTCCTGAGCGC
5' TGGCAGCTACCTGTGTCTTTCCCG
5' TAGCCACTCCTTCTGTGACTCCAGCT
5' TCTTCAAGGGACAAGGCTGCCCC
5' TGCGCTGACTCCAAAGAGACC
5' TCAAACTTGGCAATACTCATGAATGCATCCT
5' ACGGTTCACGTGCTCATGGCT
5' CAGGAGAAGGGACGCCATGCAC
5' CCCACTTCCCAGTCGGCCAG
5' TGAACCAAGGAGACGGAATACAGGGC
5' ACCTCAACCGTTCCACGTCAC
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Results
TDM induced inflammatory response in wild-type and C5a deficient bone marrow
derived macrophages.
TDM is a major generator of proinflammatory cytokines from monocytic cells
[118]. The amounts of IL-6 and TNF-α were significantly increased in the supernatants
from both wild-type C57BL/6 and C5a-deficient A/J bone marrow derived macrophages
stimulated with TDM coated microspheres (Table 2.2). Prior studies showed that
removal of surface TDM from MTB resulted in a significantly diminished
proinflammatory response [200]. A number of recent studies suggest that complement
factors play an important role in this response [97, 194]; thus, IL-6 and TNF-α were also
evaluated in bone marrow derived macrophages lacking complement C5a and infected
with MTB, or organisms from which surface TDM (delipidated; dMtb) was removed.
C5a-sufficient derived cells were used as a comparison. Delipidation of both groups
resulted in a significantly decreased cytokine response. Of importance, the C5adeficient derived cell response was always significantly decreased compared to C5asufficient derived cells. The cytokine responses were almost completely restored when
the cells were stimulated with organisms that had been reconstituted with purified TDM
(r-dMtb), suggesting the importance of TDM in generating proinflammatory responses to
MTB.

Dysregulated TDM-induced responses in TNF-α, C5a, and IL-6 knock-out mice.
Lung weight indices (LWI) were determined as an indicator of general
inflammation for wild-type and deficient mice after intravenous challenge with TDM
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TNF-α
C5a-sufficient
C5a-deficient

BSA
beads
24 (2)
14 (1)

TDM beads

MTB

dMtb

r-dMtb

uninfected

1294 (173)*
322 (19)*

541 (70)
303 (50)

253 (39)**
166 (32)**

461 (44)
339 (50)

19 (5)
10 (1)

IL-6
C5a-sufficient
C5a-deficient

7 (1)
< 10

245 (4)*
24 (4)

335 (75)
30 (1)

102 (6)**
< 10

227 (14)
< 10

5 (1)
< 10

Table 2.2. TDM induced cytokine production in C5a-sufficient and C5a-deficient
bone marrow derived macrophages. Production of TNF-α and IL-6 by bone marrow
derived macrophages to TDM-coated beads, native MTB, delipidated Mtb (dMtb),
delipidated Mtb reconstituted with TDM (r-dMtb), or untreated cells. Values were
measured by ELISA and expressed as average pg protein/106 macrophages (±SD), three
replicates per time point. *p<0.05 between treatment groups (TDM-coated vs. uncoated)
as analyzed by Student’s t test; **p<0.05 between groups compared against dMtb or
against TDM reconstituted organisms; all responses from C5a-deficient (A/J) derived
BMMs were significantly lower (p<0.05) than the C5a-sufficient (C57BL/6) BMM
treated in the identical manner.
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(Table 2.3). The wild-type, C5a -/-, and IL-6 had significantly (p<0.05) increased LWI
at both 4 and 7 days post-TDM challenge compared to untreated controls, or in
comparison to emulsion controls (data not shown, [97]). In comparison, the LWI of the
TNF-α -/- mice were unchanged after TDM-challenge, indicating that the TNF-α
deficient mice did not generate a significant inflammatory reaction to TDM.

Histopathology is altered in TNF-α, C5a, and IL-6 deficient mice in response to TDM.
C57BL/6 mice form cohesive granulomas after intravenous challenge with TDM
(Figure 2.1). Small, focal, monocytic clusters of cells were observed 4 days post-TDM
challenge. The granulomas increased in both size and number by day 7. The
granulomas were found in the lung parenchyma, without occlusion of lymphatics or
blood vessels. The granulomatous response completely resolved by day 14.
The TNF-α -/- mice did not produce a histopathological response to TDM, in
contrast to the wild-type mice. Inflammation was not observed by day 4 after TDM
challenge. On day 7, examination revealed a few cellular infiltrates that did not form
obvious granulomas; infiltrating cells were primarily monocytic. Occlusion of
vasculature, edema, and pneumonitis were not observed.
C5a deficient mice also did not generate granulomas to isolated TDM. However,
the histopathology was markedly different from the TNF-α -/- mice. The complement
knock-out mice had a marked inflammatory response that was non-focal at day 4. They
did not form cohesive cellular aggregates at day 7, and had a considerable amount of
monocytic and lymphocytic infiltrates. The lung parenchyma demonstrated occluded
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wild-type
TNF-α -/C5a -/IL-6 -/-

Day 0
1.00 ± 0.033
0.98 ± 0.026
0.93 ± 0.144
1.02 ± 0.048

Day 4
1.31 ± 0.073
0.99 ± 0.012*
1.32 ± 0.156
1.30 ± 0.051

Day 7
1.63 ± 0.232
1.01 ± 0.010*
1.53 ± 0.157
1.55 ± 0.082

Day 14
1.06 ± 0.154
0.96 ± 0.035
1.04 ± 0.196
1.19 ± 0.216

Table 2.3. Lung Weight Indices Following TDM Administration. Lung weight
indices were calculated at days 0, 4, 7, and 14 post-TDM administration. Individual
values are average responses (±SD) and compared to wild-type C57BL/6 mice (*
p<0.05) at each indicated time point.
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Figure 2.1. Granulomatous response to TDM in mice deficient in TNF-α, C5a,
or IL-6. Wild-type mice challenged with mycobacterial TDM demonstrate small
focal pulmonary granulomas by 4 days post-TDM administration, which peak at
day 7 and resolve by day 14. In comparison, challenge of TNF-α-deficient mice
did not elicit significant histopathology, with failure to mount significant
inflammation in the lung. Mice with deficiency in C5a demonstrated a non-focal
inflammatory response by day 4, and with no cellular aggregation of
accompanying lymphocytic and monocytic infiltration or true resolution by 14
days post-challenge. The IL-6-deficient mice initiated granuloma histopathology,
but by day 7 exhibited marked monocytic infiltration, lymphocytic cuffing around
occluded vesicles, and edema with accompanied alveolar cell wall thickening.
Sections representative of 4–6 mice per group. Hematoxylin and eosin staining;
magnification ×40.
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vessels and areas of pulmonary edema. Incomplete resolution of the response occurred,
with some degree of inflammation evident on day 14.
The IL-6 -/- mice appeared to initially generate granulomas after TDM challenge,
with monocytic, focal clusters visible at day 4. However, these mice did not maintain
this response. Acute inflammation was increased with considerable monocytic
infiltration apparent at day 7. Lymphocytic cuffing of occluded blood vessels was
observed, along with alveolar cell wall thickening and edema. This response appeared to
be transient, with resolution occurring by day 14.

Dysregulated cytokine and chemokine protein and mRNA expression in deficient mice
following TDM challenge
Production of cytokine and chemokine proteins were evaluated in the lungs of
mice administered TDM (Figures 2.2 and 2.3). Wild-type mice produced significantly
higher (p<0.05) IL-6, TNF-α, IL-1β, IL-12p40, IL-10, and MIP-1α on both days 4 and 7
in compared to naive mice. Additionally, there was a transient, significant, increase in
IFN-γ synthesis on day 4. Cytokine protein levels returned to near normal levels by day
14 after TDM administration.
Lung cytokine protein production in control and deficient mice was markedly
different 4 days post TDM challenge. The TNF-α knock-out mice failed to elevate
levels of cytokines and chemokines after TDM challenge. The amount of IL-6, IL-1β,
IFN-γ, IL-12p40, IL-10, and MIP-1α were not different compared to naive mice, and
were significantly below values generated by wild-type mice at all time points. TNF-α
was not produced by the TNF-α -/- mice (data not shown).
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Figure 2.2. TDM-elicited proinflammatory mediator production from lungs of
deficient and wild-type mice. Levels of pulmonary proinflammatory mediators
IL-1β, IL-6 and TNF-α were quantified post-challenge in the lungs of mice
administered TDM. Mean values per lung are shown for mice deficient in TNF-α,
C5a or IL-6 prior to challenge (day 0) and at 4, 7 and 14 days post-TDM
challenge. Comparisons are made to the wild-type control animals administered
TDM. Data are represented as the mean ± SD for duplicate wells per mouse (n =
4–6 mice per group per time point). *P < 0.05; nd, none detected.
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Figure 2.3. TDM-elicited cytokine production from lungs of deficient and
wild-type mice. Levels of pulmonary cytokines IL-12p40, IL-10, MIP-1α and
IFN-1γ were quantified post-challenge in the lungs of mice administered TDM.
Mean values per lung are shown for mice deficient in TNF-α, C5a or IL-6 prior to
challenge (day 0) and at 4, 7 and 14 days post-TDM challenge. Comparisons are
made to the wild-type control animals administered TDM. Data are represented
as the mean ± SD for duplicate wells per mouse (n = 4–6 mice per group per time
point). *P < 0.05.
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The complement C5a knock-out strain had significantly decreased lung synthesis
of IL-1β, IL-6, TNF-α, IFN-γ, and MIP-1α on day 4, in comparison to the wild-type
mice. However, levels of protein became comparable to wild-type mice by day 7. MIP1α, a chemokine that directs migration of a variety of effector cells, was significantly
decreased in the C5a deficient mice at day 4. Additionally, IL-12p40 was also
significantly reduced on all time points compared to complement-sufficient mice.
The IL-6 -/- mice also had decreased synthesis of IL-1β, TNF-α, IL-12p40 and
IFN-γ in the lungs 4 days after TDM administration. The levels of these cytokines were
similar to the wild-type mice by day 7. IL-10 levels were significantly reduced at day 7
in the IL-6 knock-out mice. MIP-1α levels were not significantly different from the
wild-type mice on any time points tested. Production of IL-6 protein in the IL-6
deficient mice was below the limit of detection (data not shown).
Examination of mRNA in wild-type and deficient mice given TDM generated
similar results to lung protein levels (Table 2.4). The wild-type C57BL/6 mice produced
a significant increase (20-fold or greater) in proinflammatory message of IL-1β, IL-6,
TNF-α, and MIP-1α, in comparison to naive or emulsion treated controls (not shown). A
modest increase in IL-12p40 was noted on both days 4 and 7. There was additionally an
early rise in expression of IL-10 and IFN-γ that decreased on day 7. The deficient mice
had reduced expression of all cytokines examined, with the exception of IL-12p40, in
comparison to wild-type mice. Significant differences in message levels in the knockout
strains compared to wild-type control mice (p<0.05) are shown in Table 2.4. Expression
of IL-6 or TNF-α in the IL-6 -/- mice or the TNF-α -/- mice, respectively, was not
observed.
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Table 3. Relative Change in mRNA Following TDM administration a
IL-1â

IL-6

TNF-á

MIP-1á

IFN-ã

IL-12p40

IL-10

Day 4
wild-type
TNF-á -/C5a -/IL-6 -/-

23.89 ± 9.37
3.79 ± 2.24*
15.25 ± 1.94*
5.02 ± 1.42*

32.01 ± 7.71
5.45 ± 3.41*
16.57 ± 6.76
---

20.71 ± 3.67
--31.34 ± 13.99
5.72 ± 1.50*

29.57 ± 10.59
4.61 ± 1.87*
19.59 ± 20.04
5.54 ± 2.00*

23.09 ± 14.60
4.12 ± 1.76*
12.43 ± 2.10*
7.02 ± 2.48*

2.99 ± 0.32
3.21 ± 1.74
1.35 ± 0.98
2.04 ± 1.02

29.17 ± 17.71
7.10 ± 4.02*
11.45 ± 7.86*
7.02 ± 3.22*

Day 7
wild-type
TNF-á -/C5a -/IL-6 -/-

32.96 ± 10.66
2.54 ± 1.73*
15.94 ± 4.17*
5.04 ± 1.77*

27.87 ± 26.62
1.08 ± 0.88*
3.28 ± 0.97 *
---

43.59 ± 13.60
--18.44 ± 10.55*
5.97 ± 2.21*

42.51 ± 16.84
2.32 ± 1.77*
16.36 ± 10.88*
7.04 ± 1.89*

9.63 ± 5.95
2.31 ± 1.36
10.57 ± 5.37
2.18 ± 0.87

2.19 ± 0.72
0.89 ± 0.68
1.79 ± 0.45
0.95 ± 0.55

11.84 ± 3.34
2.49 ± 1.64
5.73 ± 1.20
2.07 ± 0.81

Day 14
wild-type
TNF-á -/C5a -/IL-6 -/-

0.61 ± 0.20
2.30 ± 1.25
0.68 ± 0.55
2.01 ± 1.32

0.53 ± 0.05
1.50 ± 1.53
0.44 ± 0.22
---

10.29 ± 15.73
--0.63 ± 0.60
3.29 ± 2.72

0.72 ± 0.56
2.14 ± 1.14
0.94 ± 0.55
2.65 ± 1.05

1.75 ± 1.04
3.42 ± 1.97
1.37 ± 1.48
2.56 ± 1.71

1.09 ± 0.29
1.13 ± 0.69
1.58 ± 1.19
1.35 ± 0.60

0.67 ± 0.30
2.16 ± 1.39
1.79 ± 2.24
3.41 ± 2.29

Table 2.4. Relative Change in mRNA following TDM administration.
Proinflammatory mediator mRNAs in lungs of mice deficient in TNF-α, C5a, or IL-6
were evaluated by RT-PCR and compared to wild-type controls, after challenge with
TDM. Results shown are normalized to β-actin, and represented as fold-change from
non-injected mice. Data are expressed as mean values with standard deviations. *
p<0.05.
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Discussion
Approximately one-third of the world’s population is considered latently infected
with MTB [203]. Granuloma formation is an essential host response for containment of
the bacilli and requires concerted regulation of immunological mediators. An increasing
number of chemotherapeutics that target cytokines for the treatment of immunemediated diseases makes it essential to explore how cytokines are involved in the
initiation and maintenance of MTB-induced granulomas. For example, use of the TNF-α
neutralizing antibody infliximab resulted in modulated inflammatory patterns that caused
reactivation of latent pulmonary TB and greater occurrences of extrapulmonary disease
[204]. Furthermore, cytokines are being considered as adjunct therapeutics to enhance
antibiotic efficacy for TB treatment in cases of multidrug-resistant strains and
immunodeficient patients [205, 206]. An understanding the implications of cytokine
dysregulation on granulomatous responses is essential when evaluating treatment for
these individuals.
TNF-α is a central mediator in initiation of granuloma formation. TNF-α
deficient mice did not generate granulomas following challenge with MTB, instead
forming necrotic lesions lacking epithelioid cells [207]. The TNF-α deficient mice in the
results reported in this study did not generate a histological response following challenge
with TDM, accompanied by markedly reduced cytokine protein and message synthesis.
Of importance, these deficient mice also had decreased amounts of the Th1 cytokines
IL-12p40 and INF-γ. A study by Kindler and colleagues [190] noted that antibody
neutralization of TNF inhibited granuloma formation following infection with BCG and
dissolved chronic granulomas. Transgenic mice producing high levels of human soluble
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TNF receptor 1 also did not form granulomas to BCG, accompanied by delayed
synthesis of both IL-12p40 and IFN-γ [208]. The absence of granuloma generation in
TNF-α -/- mice is possibly a result of an inability to synthesize a cytokine cascade that
includes chemokines that recruit both monocytes and T-cells to lung tissue. TNF
neutralization in macrophage cultures infected with MTB resulted in a decrease in
synthesis of CCL5, CXCL9, and CXCL10 [209]. The same investigation reported that
CD11b+ cells recovered from mice deficient in the 55 kDa TNF receptor and infected
with MTB had delayed synthesis of chemokines. Additionally, TNF-α is an essential
regulator of Th1 immune responses necessary for control of mycobacterial infections.
Treatment of macrophages with a TNF-neutralizing antibody or macrophages deficient
in the TNF receptor 1 did not synthesize IL-12 following BCG infection [210]. TNF-α
was necessary for the initiation of IL-12-induced Th1 responses in BALB/c mice [211].
Furthermore, Ahlers et al. [212] reported that a synergism between TNF-α and IL-12
was essential to promote the IL-12Rβ2 chain and IFN-γ to induce the development of
Th1 cells. The essential role of T cells in TDM-induced granulomas has been explored
[120, 213], with T helper cells of central importance for the generation of hypersensitive
pathology [120, 214].
The studies reported here suggest that complement C5a is necessary for
development of cohesive granulomas following challenge with mycobacterial glycolipid
TDM, once the response is initiated. C5a deficiency resulted in development of
pneumonitis pathology accompanied by edema and monocytic infiltration with
incomplete resolution of inflammatory responses, suggesting a role for C5a in
granuloma maintenance and resolution. Furthermore, the complement knock-out mice
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had reduced early synthesis of proinflammatory cytokines accompanied by consistently
decreased production of IL-12p40. A/J mice, which are deficient in the fifth component
of complement along with other defects, failed to generate granulomas and had increased
mortality to MTB infection [98]. A study using the same C5a deficient mice used in this
investigation reported increased MTB growth in lung tissue in addition to failing to form
granulomas [97]. Both investigations reported early decreases in cytokines and
chemokines, similar to results presented here for the chemokine MIP-1α. Complement
C5 is necessary for variety of additional processes that are possibly involved in
granuloma formation or maintenance. C5a promotes NFκB, a regulator of expression of
a number of inflammatory mediators, including TNF-α and IL-6 [215]. Both C5a and
C5b induce adhesion molecule expression on neutrophils, endothelial cells, and
macrophages [216, 217]. Finally, C5 is necessary for IL-12 generated cell-mediated
immunity [218].
The investigations presented here additionally suggest that IL-6 plays a role in
maintenance of established granulomas, but not in their initiation. The IL-6 -/- mice
generated similar granulomas to wild-type mice after TDM challenge at day 4. Of
significance, this occurred in the presence of decreased levels of proinflammatory
cytokines. However, the granulomatous response was not maintained through day 7,
despite levels of cytokines similar to those of wild-type mice. The IL-6 deficient mice
had severe, edematous pathology; a recent investigation demonstrated that IL-6 is
necessary for regulating local concentrations of glucocorticoids that modulate
pathological responses [219]. Investigations on the role of IL-6 in control of
mycobacterial infections have yielded conflicting results. Even less is known of the role
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IL-6 plays in granuloma formation during MTB infection. Ladel and coworkers [107]
reported that IL-6 deficient mice had significantly higher bacterial loads and ultimately
succumbed to infection, while Saunders and colleagues [105] demonstrated that mice
lacking IL-6 were able to contain the infection in the presence of higher bacterial
burdens and decreased early IFN-γ production. The conflicting results between these
two studies may be due to the number of organisms and routes used for the infectious
challenge. Further complicating interpretation, M. avium-infected mice treated with IL-6
neutralizing antibodies had increased bacterial loads; however, no differences in
granuloma size or number were observed [220]. Infection of IL-6 knock-out mice with
M. avium resulted in fewer necrotic lesions in comparison to wild-type mice [221]. IL-6
-/- mice infected with Rhodococcus aurantiacus, an organism that produces short chain
TDM and induces Th1 granulomas that are similar to those induced by mycobacterial
organisms, reported increased inflammatory infiltrates after challenge and granulomas
that were increased in size and had central necrosis in comparison to the wild-type mice
[222]. IL-6 is generally thought of as a Th2 cytokine [195, 223]. However, this may not
be a stand-fast rule in all models of intracellular infections [224]. IL-6 has been reported
to play a role in the development of T-cell responses against M. avium [220]. It is wellestablished that maintenance of the granulomatous response requires antigen-specific Tcells [225]. Thus, IL-6 is possibly a regulator of T-cell responses that are essential for
maintenance of established granulomas, especially when persistent antigen is present.
The TDM model of granuloma formation mimics in part certain aspects of
mycobacterial histopathology seen during aerosol challenges of mice. Thus, this model
may be useful for investigations of the roles of complement and certain cytokine
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mediators involved in the early response to mycobacterial glycolipid antigens. The
investigations reported here suggest that TNF-α is an essential mediator required in
initiation of TDM-induced granulomas (Figure 2.4). Once the granulomas have been
initiated, mediators such as complement component C5a and IL-6 generate secondary
responses. C5a is most likely is an important regulator of responses that generate
cohesive granuloma pathology, while IL-6 is involved in the maintenance of established
granulomas. Deficiency of any of these mediators results in an inability to effectively
generate and maintain a granulomatous response, and would thus also likely be
important in the control of mycobacterial infections.
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Figure 2.4. Proposed mechanism for TDM-induced granulomas. TNF-α is
essential for a histological response to TDM. Once a response has been initiated,
complement C5a and IL-6 recruit cells that produce regulating cytokines and
upregulate integrin that allow cells to form organized, cohesive structures.
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Chapter Three
Lactoferrin decreases mycobacterial antigen induced lung immunopathology
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The studies presented in this chapter were published in the journal Translational
Research, 2010 156: 207 – 15 [226]

Introduction
Tuberculosis (TB) causes approximately 1.8 million deaths annually, making it
the leading cause of death worldwide due to bacterial infections [203]. Additionally,
roughly one-third of the world’s population is considered latently infected with
Mycobacterium tuberculosis (MTB) [203]. Effective chemotherapy for TB is available;
however, treatment requires at least six months of a complex multi-drug regimen for
which effectiveness is threatened due to the emergence of multi-drug resistant
organisms. Unfortunately, there have been no new commercial antibiotics against TB
created since rifampin was invented in the 1960s [3]. Therefore, new agents with
activity against MTB or a favorable effect when used in combination with the standard
anti-TB drugs are desperately needed.
The normal, immune competent host responds to infection with MTB by forming
granulomas, which structurally consist of central infected macrophages that can
differentiate into foamy macrophages, epithelioid cells, and Langhan’s giant cells [17].
A layer of fibrosis develops and surrounds the infected macrophages, which prevents
bacterial dissemination. However, granulomas also result in physical separation of
infected cells from effector lymphocytes that are capable of eliminating infected cells
[17]. Additionally, the TB bacilli enter a state of non-replicating persistence within
granulomas; these organisms are resistant to sterilizing antimicrobials [131, 132]. Most
granulomas heal, but viable MTB persist. Individuals at this stage of infection are
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known as latently infected because they do not have clinical symptoms of disease,
sputums do not contain acid-fast bacilli, and chest X-rays are stable [227]. However, a
small percentage of patients experience reactivation of latent disease that histologically
is characterized as a lipid pneumonia that may undergo necrosis to generate cavitary
lesions [11]. The resulting lung damage causes a productive cough that generates
infectious aerosols, which may infect a new individual. Therefore, modulation of TBinduced inflammatory pathology will likely decrease morbidity, facilitate improved
response to antibiotics, and limit disease transmission.
Increasing evidence identifies lactoferrin as a modulator of the immune response
to a number of inflammatory and injurious agents. Lactoferrin is a component of the
transferrin family of glycoproteins and is produced in neutrophil granules and mucosal
secretions [140]. Lactoferrin receptors are found on numerous cells of the immune
system, such as macrophages, dendritic cells, and T-cells [144-146]. Lactoferrin effects
include macrophage activation, enhancement of polymorphonuclear cell phagocytosis,
increasing killer cell activity, and maturation of B- and T-cells [148, 149, 228-230]. Of
significance, lactoferrin alters macrophage cytokine production depending on the
environmental context [142, 156, 231]. For example, addition of lactoferrin to
macrophages stimulated with low levels of LPS produced increased levels of
proinflammatory cytokines [175]. However, macrophages fully stimulated with LPS
and given lactoferrin had decreased cytokine production. Of importance to the studies
proposed here, lactoferrin protects against immune-mediated tissue damage in a number
of model systems. Mice injected with LPS and treated with lactoferrin had decreased
gut tissue destruction and increased survival [140, 183]. Additionally, lactoferrin as an
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adjuvant to the BCG vaccine resulted in decreased lung damage and increased protection
following an aerosol TB challenge [232].
Trehalose-6’6-dimycolate (TDM) is the most abundant glycolipid produced by
MTB. TDM has multiple hypothesized roles in MTB pathogenesis [13], including
involvement in the formation of lung caseation [110]. TDM prepared in emulsion form
and injected into mice intravenously induces lung pathology that mimics certain aspects
of MTB infection, such as production of proinflammatory cytokines and granuloma
formation. The TDM granuloma model has been used to explore the immunological
mediators involved in initiation of the granulomatous response [119, 130]. TDM
induces foreign body granulomas in naïve mice [118, 233], and hypersensitive
granulomas in previously sensitized mice [69, 110, 121, 213]. Thus, this model system
may be used to explore the potential of immunomodulators to modulate granuloma
structure.

Materials and Methods
Animals. Four-week old, female C57BL/6 mice were purchased from the
Jackson Laboratories (Bar Harbor, ME). Animal studies were conducted under approval
by the UTHSC Institutional Review Board (protocol number HSC-AWP 07-093). Eight
mice were used per group, for the time points indicated.
Lactoferrin and MTB. Bovine-derived lactoferrin (>95% purity, <20% iron
saturated, <0.2 endotoxin units/mg) was purchased from PharmaReview Corporation
(Houston, TX). Lactoferrin was dissolved in phosphate buffered saline (PBS), and
stored at -80°C until use.
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MTB Erdman (American Type Cell Culture 35801) was grown in 7H9 broth
(Remel, Lenesa, KS) with 10% supplement at 37°C to logarithmic phase. The MTB
were diluted in 1X PBS using McFarland standards (Sigma, St. Louis, MO) to 3 x 108
bacteria per ml. The final bacterial concentration was confirmed by plating serial
dilutions onto 7H11 plates (Remel), and counted after incubating at 37°C for 3-4 weeks.
Generation of bone marrow-derived macrophages (BMM), stimulation with
TDM-coated beads, and MTB infection. BMMs from C57BL/6 mice were generated by
previously detailed procedures [155]. McCoy’s medium (Sigma) was used to flush
femurs, followed by adding 5 x 105 of the recovered cells to 24-well tissue culture plates
(Corning, Corning, NY). The cells were cultured in McCoy’s medium supplemented
with 10% fetal bovine serum (FBS) (Sigma), antibiotics (100 µg/ml penicillin G and 50
µg/ml gentamycin) (Sigma), and 10 ng/ml recombinant murine granulocyte/macrophage
colony stimulating factor (GM-CSF) (Cell Sciences, Canton, MA). Cells were cultured
at 37°C with 5% CO2 for one week, with two additional media changes containing GMCSF. The cells were washed one time with 1X PBS and the media changed to
Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS, 0.01% HEPES (Sigma),
and 0.01% L-arginine (Sigma). The cells were rested overnight and then stimulated with
TDM-coated microspheres or infected with MTB.
TDM- and BSA-coated beads were generated as per previously described
methods [23], and were a generous gift from C. Kan. The beads were briefly sonicated
and then added to the BMMs at a ratio of 10 beads per one cell with or without 100
µg/ml lactoferrin that was added simultaneously with bead stimulation or three hours
later. Alternatively, the BMM were infected with MTB using a multiplicity of infection
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(MOI) of 1:1 in the presence or absence of lactoferrin (100 µg/ml) added at the same
time as infection or three hours after. For both bead stimulation and infection, the
supernatants were collected after 24 and 72 hours of incubation and analyzed for
cytokine protein production by ELISA (see below).
In vivo challenge with TDM, tissue processing, and lung immunopathology. An
oil-in-water emulsion of TDM was generated by previously described methods [118,
119]. Briefly, mice were intravenously injected in the tail vein with 50 µl of the
emulsion. The TDM emulsion was generated by dissolving 25 µg of purified TDM
(Sigma) in 9:1 hexane/ethanol, after which the solvent was evaporated. Two percent
Drakeol (Penreco, Dickinson, TX) was homogenized into the TDM. Finally, 0.2%
Tween 80 (Mallinckrodt, Hazelwood, MO) in PBS was admixed. A control emulsion
lacking TDM was also generated. Subsets of mice were given either 1 mg of lactoferrin
or 1 mg of bovine apo-transferrin (Sigma) in 100 µl of PBS that was administered
intravenously 24 hours after TDM challenge.
Mice were sacrificed at 0, 4, and 7 days after challenge with TDM. The lungs
were immediately removed, weighed, and sectioned for cytokine analysis or histological
studies. Approximately 30 mg of lung tissue was minced and put into 2 ml of DMEM
and cultured at 37 °C for 4 hours. The supernatants were collected and stored at -20 °C
until ELISA analysis for cytokine protein production. For histological studies, the left
lung was fixed in 10% buffered formalin, sectioned (5 µm), and stained with
hematoxylin and eosin per standard methods. The entire 5 µm lung section for at least 6
mice per group was photographed with a 2x objective. A quantitative analysis was
performed with the NIH Image J program (U.S. National Institutes of Health, available
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at http://rsb.info.nih.gov/nih-image/). The total number of granulomas was counted over
an entire section of the lung. The average granuloma size was calculated using a random
selection of 10 granulomas in 3 different microscopic fields for each mouse.
The lung production of IL-1β, IL-6, TNF-α, IL-12p40, IL-10, IFN-γ, and TGF-β
was determined using a sandwich ELISA according to the manufacturer’s instructions
(R&D Systems, Minneapolis, MN). The average of duplicate wells was determined by a
standard curve created for each assay by use of manufacturer supplied recombinant
molecules. The limit of detection sensitivity was 15-32 pg/ml, according to the
manufacturer.
Statistics. The data are shown as the mean ± 1 SD. Two-way ANOVA was used
to evaluate the differences between groups using GraphPad Prism software (GraphPad
Software, La Jolla, CA). Statistical significance was defined as a p-value of < 0.05.

Results
Lactoferrin modulates bone marrow-derived macrophage inflammatory response to
isolated TDM.
TDM induces proinflammatory cytokine production by macrophages [17, 118,
200]. TNF-α, IL-6, and IL-12p40 production were significantly increased in BMMs
stimulated with TDM-coated microspheres, in comparison to macrophages given BSAcoated beads (Figure 3.1). In contrast, TGF-β production significantly decreased with
TDM-bead challenge. Treating the BMM with 100 µg/ml bovine lactoferrin
simultaneously with TDM bead stimulation or three hours later resulted in markedly
decreased synthesis of TNF-α, IL-6, and IL-12p40 that was accompanied by increased
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Figure 3.1. Lactoferrin modulation of TNF-α, IL-6, IL-12p40, and TGF-β
production by BMM in response to TDM-coated beads. Cells were treated
with 3 µm BSA- or TDM-coated beads alone at a ratio 0f 10:1, 100 µg/ml
lactoferrin at the same time as beads stimulation, or 100 µg/ml lactoferrin 3
hours after bead addition. Values were measured by ELISA and expressed as
mean pg/ml with SD. * p<0.05 compared to treatment with TDM-coated beads
alone.
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production of TGF-β. TGF-β was elevated when the cells were stimulated with control
BSA-coated beads and given lactoferrin, as has been previously described [157].

Lactoferrin decreases TDM-induced immunopathology.
C57BL/6 mice challenged with TDM generated lung granulomas following a
single intravenous dose. Focal, small, monocytic clusters were visible by 4 days after
challenge with TDM (Figure 3.2A). Granuloma size and number increased by day 7
(Figure 3.2B) and was accompanied by other pathological manifestations, such as
perivascular cuffing of lymphocytes. Mice given an emulsion control without TDM did
not generate granulomas and had normal lung histology. Mice administered TDM and
treated with 1 mg of intravenous bovine lactoferrin 24 hours after challenge had smaller
and fewer granulomas, with the granulomatous response significantly decreased at 7
days. This response is not likely attributed to lactoferrin’s iron binding capacity because
mice given transferrin, an iron-binding control, did not have altered granuloma size or
number.

Lung cytokine protein levels in mice challenged with TDM and treated with lactoferrin.
The levels of lung cytokines were examined in mice administered TDM (Figures
3.3 and 3.4). Mice challenged with the TDM emulsion had significantly increased levels
of IL-1β, IL-6, TNF-α, IL-12p40, and IFN-γ at 4 and 7 days post-challenge in
comparison to mice given an emulsion control without TDM (Figure 3.3). Mice given 1
mg of bovine lactoferrin intravenously 24 hours post-TDM administration produced

Day 4

A.

Day 7
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Figure 3.2. Granulomatous response to TDM in lactoferrin treated mice. A)
Mice were challenged with 25 µg TDM prepared in a water-in-oil emulsion. One
mg of lactoferrin or transferrin (not shown) was administered 24 hours post-TDM
challenge. Hematoxylin and eosin staining, magnification 100X. B) Number of
lung granulomas per mm2 and the size of the granulomas (µm2). Granulomas were
enumerated and measured as described in the materials and methods section. Data
are expressed as the mean ± SD. * p<0.05 with comparisons made to the mice
administered the TDM emulsion.
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Figure 3.3. Production of pro-inflammatory mediators in mice challenged with
TDM alone or with lactoferrin. The levels of TNF-α, IL-1β, IL-6, IL-12p40, and
IFN-γ in lung tissue were determined by ELISA. Data are shown as the mean with
standard deviation. N = 8 mice per group, per time point. *p<0.05 with
comparison to the TDM emulsion treated mice.
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Figure 3.4. Lactoferrin induced production of anti-inflammatory
cytokines in TDM challenged mice. The levels of IL-10 and TGF-β were
quantified in lung tissue homogenates by ELISA. Data are expressed as the
mean with standard deviation. N = 8 mice per group, per time points
indicated. *p<0.05, comparisons made to the TDM-treated mice.
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similar levels of most pro-inflammatory cytokines, except for decreased IL-1β at day 7.
Of potential significance, the levels of TNF-α and IFN-γ were not significantly altered in
the mice treated with lactoferrin. In comparison, the amounts of IL-10 and TGF-β,
cytokines that can have anti-inflammatory functions, were elevated at day 4 and day 7,
respectively, in the mice treated with lactoferrin (Figure 3.4). Mice given transferrin 24
hours after the mice were challenged with TDM produced similar levels of cytokines in
comparison to the mice administered a TDM emulsion alone.

Lactoferrin modulation of BMM cytokine production in response to mycobacterial
infection
Certain proinflammatory cytokines such as TNF-α are of critical importance for
host defense during MTB infection [190, 207, 234]. Thus, there was concern that the
decrease in TNF-α production from BMMs stimulated with TDM-coated beads and
treated with lactoferrin may produce favorable conditions for MTB proliferation within
host cells. Thus, C57BL/6 BMMs were infected with MTB in the presence or absence
of lactoferrin. Production of cytokines in response to MTB infection is presented in
Figure 3.5. TNF-α levels were significantly increased in BMMs treated with lactoferrin
either simultaneously with bacterial seeding or three hours after. IL-6 was significantly
decreased, and IL-12p40 production was not altered. Additionally, TGF-β was
significantly elevated at 72 hours post-infection. These data suggest a potential for
lactoferrin to decrease the cytokines responsible for tissue destruction while maintaining
production of those essential for the generation of responses necessary for protection
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Figure 3.5. Lactoferrin modulation of BMM cytokine production in response
to MTB infection. BMM were infected with MTB Erdman using a MOI of 1:1.
100 µg/ml of bovine lactoferrin was added at the same time as infection or 3 hours
after infection. The levels of TNF-α, IL-6, IL-12p40, and TGF-β were measured
in the filtered supernatants 24 and 72 hours after infection by ELISA. Data are
shown as the mean and SD. *p<0.05, comparisons are to cells infected with MTB
alone.
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against mycobacteria. Lactoferrin alone does not alter the proliferation of MTB within
macrophages (Chapter 4).

Discussion
MTB causes approximately 1.8 million deaths annually and infects nearly onethird of the world’s population [203]. The number of cases of this disease continues to
rise, possibly due to the emergence of multi-drug resistant organisms and HIV coinfection [133]. The therapy for TB is complex, lengthy, and requires antibiotics that
have significant side-effects, often resulting in poor compliance to treatment. The World
Health Organization’s directly observed therapy short-course (DOTS) program is
effective, but puts a significant financial burden on the resource poor countries that are
disproportionately impacted by TB. Therefore, new agents that can shorten TB
treatment are needed. Agents with immunomodulatory functions, such as lactoferrin, are
a novel approach to TB treatment in that they may be able to circumvent drug resistance.
Additionally, lactoferrin’s ability to decrease immune-related pathology may enhance
antibiotic penetration into tissue and augment the generation of immune responses that
can kill latent bacilli [131, 133].
TDM is a highly immunostimulatory glycolipid synthesized by MTB. Challenge
with a single dose of TDM results in recruitment of immune cells to lung tissue
accompanied by production of cytokines that are similar to those synthesized during
natural TB infection [17, 110]. The data presented here demonstrate that mice treated
with lactoferrin following challenge with TDM had decreased lung immunopathology at
the height of the granulomatous response. Alteration of granuloma structure has a
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number of potential implications for the therapy of both active and latent TB. MTB
within granulomas convert to a state of non-replicating persistence that is characterized
by changes in biochemical pathways and decreased replication [15, 131, 132].
Antimicrobial agents require actively replicating bacilli for effectiveness and are
therefore unable to kill the dormant MTB isolated within granulomas. Additionally, it is
hypothesized that decreasing lung immunopathology may enhance the penetration of
antibiotics within infected tissue, thereby enabling a faster response to TB chemotherapy
[15, 133]. Use of TB antibiotics in combination with immunomodulators has generated
promising results in human clinical studies. One clinical trial evaluated addition of the
soluble TNF-α receptor etanercept to antibiotic therapy in HIV patients with TB; there
was significantly lessened time to sputum culture conversion accompanied by improved
chest x-rays in the patients given the combination of anti-TB agents and etanercept
[135]. Another trial explored combining high-dose prednisolone with anti-TB agents in
patients co-infected with HIV and TB [136]. Sputum culture conversion rate was
significantly increased in patients treated with prednisolone, in comparison to antibiotics
alone. Use of lactoferrin in combination with TB therapy has numerous advantages over
other immunomodulators in use because it does not suppress the immune system and has
a proven safety record in a number of animal models and human studies [134, 138, 139,
235, 236].
A hypothesized mechanism for the reduction in lung pathology in lactoferrin
treated mice is the increased synthesis of TGF-β and IL-10, cytokines that have essential
roles in decreasing pathology due to the immune system [58]. It is possible that TH2
cytokines may decrease protective immune responses to TB [131]. However, the
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cytokines considered critical for host defense against TB, IFN-γ and TNF-α [46], were
not significantly altered by treatment with lactoferrin. IFN-γ is necessary for control of
mycobacterial burden; an example of the importance of this cytokine is the severe
mycobacterial infections that occur in patients deficient in IFN-γ signaling factors [237].
TNF-α is necessary for initiation and maintenance of granulomas; deficiency of TNF-α
results in reactivation of latent disease and severe necrotic pathology [15, 46, 238].
Lactoferrin’s ability to generate an anti-inflammatory response simultaneously with proinflammatory cytokine synthesis has been described in other studies [140]. For example,
lactoferrin administered orally to rats in a model of colitis increased the Th2 cytokines
IL-4 and IL-10 [186], in addition to decreased immune-mediated pathology in mouse
LPS sepsis models [183, 239]. In comparison, lactoferrin increased the delayed-type
hypersensitivity response to ovalbumin, BCG, and sheep red blood cells [170, 171, 228].
Lactoferrin’s ability to produce pro-inflammatory and anti-inflammatory responses
makes it an ideal immunomodulator for a number of inflammatory and infectious
diseases.
We report that macrophages treated with lactoferrin and infected with MTB
produced higher levels of TNF-α. This is in marked contrast to the overall reduction in
proinflammatory cytokines when the BMM where stimulated with TDM-coated
microspheres and given lactoferrin. This is possibly attributed to the fact that MTB
produces a variety of immunostimulatory moieties in addition to TDM, such as ligands
for the toll-like receptors, NOD-like receptors, and C-type lectins [123]. Of
significance, these experiments found that lactoferrin alone did not alter MTB growth in
BMMs. However, lactoferrin does have an impact on the growth of MTB in
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macrophages, but only if the macrophages are activated with IFN-γ in addition to
lactoferrin treatment (Chapter 4). The data presented here on infected macrophages
indicate the necessity to determine the impact of lactoferrin in MTB infection models.
The TDM granuloma model mimics certain aspects of the immune responses
observed in murine aerosol infections. This model system is thus ideal for screening
immunomodulatory agents that may alter TB-induced lung pathology. These studies
suggest that lactoferrin may decrease lung pathology in a TB granuloma model while
maintaining protective immune responses. Lactoferrin may thus have potential
advantages as an adjuvant therapeutic in the treatment of TB.
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Chapter Four
Lactoferrin as a therapeutic to modulate Mycobacterium tuberculosis induced
immunopathology
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Introduction
Tuberculosis (TB) remains a significant global public health burden. There are
approximately 9.27 million new cases of this disease and nearly two million deaths each
year [1]. Over 95% of drug-susceptible Mycobacterium tuberculosis (MTB) can be
cured with a four-drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol for
two months followed by four additional months of isoniazid and rifampin [2]. However,
the lengthy, complex drug regimen required to treat TB is difficult to administer in the
resource poor countries that TB disproportionately affects. Furthermore, the efficacy of
the available drug regimen is threatened by the emergence of multi-drug resistant strains
[1]. The last major advancement in TB therapeutics was made when rifampin was
introduced in the 1960s [7]. Thus, there is considerable need to develop novel agents for
the treatment of TB.
Th1 responses are critical for host defense against MTB [46]. MTB infection
begins with uncontrolled growth of the TB bacilli within macrophages. An innate
granuloma forms due to the accumulation alveolar and recruited systemic macrophages.
Dendritic cell presentation of TB antigens to naive CD4+ T-cells in the presence of IL12 generates a Th1 immune response [240]. Interferon-gamma (IFN-γ) production by
Th1 cells activates macrophages, resulting in phagosome acidification, phagolysosome
fusion, and synthesis of reactive nitrogen species that kill MTB [46]. CD4+ T-cells are
also essential for the generation of CD8+ cytotoxic T-cells that may play a role in
control of disease progression [46]. An example of the importance of the CD4+ T-cell
response can be found in humans with advanced HIV, who develop disseminated
mycobacterial infections when CD4+ T-cells reach low levels [45]. Additional immune
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system responses are also likely important. For example, a number of studies have
highlighted the role of IL-17 in the immune response against MTB [64, 65, 241].
Specifically, early enhancement of IL-17 responses by use of an IL-23 producing
adenovirus during MTB infection resulted in decreased bacterial burden and reduced
lung pathology [67]. Therefore, immunomodulatory agents useful in control of MTB
infection are expected to produce a strong Th1 response, and perhaps IL-17 mediated
responses.
Modulation of immune-mediated pathology while preserving essential immune
responses may represent a novel therapeutic strategy for the treatment of TB. The
immunocompetant host responds to MTB infection by the formation of granulomas,
which may prevent dissemination of the bacilli [17]. However, MTB within granulomas
are protected from immune-mediated killing due to the sequestration of infected
macrophages from immune effector cells [15]. MTB within granulomas adapt by
conversion to a dormancy phenotype that includes decreased replication and changes in
biochemical pathways, making the bacilli relatively resistant to the action of sterilizing
antimicrobials [131, 132]. Furthermore, decreasing lung immunopathology may
enhance antibiotic penetration in infected tissue, thus promoting a faster response to
antimycobacterials [15, 133].
A number of studies suggest that lactoferrin has a number of immune modulating
properties that may be favorable to the host during MTB infection [140]. Lactoferrin is
an iron-binding glycoprotein member of the transferrin family that is found in mucosal
secretions and neutrophil granules. Specific effects of lactoferrin include macrophage
activation, enhancement of phagocytosis, and enhancement of the delayed type
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hypersensitivity response to a number of antigens [140]. Importantly, lactoferrin
enhances Th1 immune responses in a number of model systems, a response essential for
host defense against MTB [134, 140, 155, 157, 242, 243]. Critical to the studies
proposed here, lactoferrin has been shown to protect against immune-mediated tissue
damage. For example, mice treated with lactoferrin had increased survival and
decreased gut tissue destruction after LPS injection [183]. Additionally, lactoferrin
added to the BCG vaccine resulted in increased protection against an aerosol TB
challenge, with evidence of decreased lung damage [232].
These studies explored the ability of lactoferrin to modulate lung pathology
during a mouse of MTB infection using a rapidly proliferating variant of MTB Erdman.
We found that lactoferrin added to the drinking water during MTB infection decreased
organ bacterial burden and lung immunopathology. Lung immune responses were
explored to determine the ability of lactoferrin to promote protective Th1 and IL-17
mediated responses.

Materials and methods
Animals. Four week-old, female C57BL/6 mice were purchased from Jackson
Laboratories. All studies were conducted under the approval from the animal ethics
committee at the UTHSC, protocol AWC-08-050. Four to six mice were used per group,
per time points indicated. All MTB infections occurred in biosafety level 3 facilities.
Lactoferrin and MTB. Bovine-derived lactoferrin (15 – 20% iron saturated, <0.2
endotoxin units/mg) was supplied by PharmaReview Corporation (Houston, TX). A
rapidly-proliferating variant of MTB Erdman (TMC 107, American Type Cell Culture)
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was cultured in Middlebrook 7H9 broth with 10% supplement (5% bovine serum
albumin, 2% dextrose, and 0.5% Tween 20 in distilled water) to log phase. Pelleted
bacteria were resuspended in phosphate buffered saline (PBS) and diluted to 3 x 108
colony forming units (CFU) per ml using McFarland standards. Bacteria were sonicated
to disperse aggregates. The bacterial CFUs were confirmed by plating serial dilutions on
Middlebrook 7H11 agar plates (Remel, Lenexa, KS), which were incubated at 37 °C for
3 – 4 weeks.
Acute tuberculosis infection of mice. MTB strain Erdman was cultured to log
phase as described above. C57BL/6 mice were infected using an aerosol inhalation
exposure system (GLAS-COL Model #A4212 099c) to achieve an aerosol implantation
of 100 CFUs. The inoculation dose was confirmed by sacrificing a subset of mice at day
one post-challenge, and the lung bacterial load determined by plating lung homogenates
onto 7H11 agar plates. The mice were randomized to either untreated controls or mice
treated with lactoferrin at the start of infection to determine the effect of lactoferrin prior
to development of histopathology, or beginning 7 days later to evaluate the impact of
lactoferrin on established infection. Lactoferrin was administered in the drinking water
at 5 mg/ml to give a dose of approximately 20-25 mg per mouse, assuming mice drink 45 ml of water per day [244], as was done in prior studies of oral lactoferrin-mediated
immune modulation [180, 245]. Mice were sacrificed at 1, 2, and 3 weeks postinfection. The lung, spleen, and liver were aseptically removed, placed into 5 ml of
PBS, and homogenized. Serial dilutions of organ homogenates were plated onto
Middlebrook 7H11 agar plates and incubated for 3 – 4 weeks at 37 °C.
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Lung histopathology analysis. Lung tissue was fixed in 10% formalin and
embedded in paraffin. Five µm thick sections were stained with hematoxilin and eosin
by standard methods. Acid-fast staining was performed by the Zhiel-Neelsen method.
Twelve lungs from each group pooled from two different experiments at three weeks
post-challenge were randomly selected for immunohistochemistry (IHC) for CD4 and
CD8. Rat anti-mouse monoclonal antibodies (R&D Systems, Minneapolis, MN) were
used to detect CD4+ and CD8+ cells, with detection using an anti-rat horseradish
peroxidase 3,3’diaminobenzidine cell and tissue staining kit according to the
manufacturer’s instructions (R&D Systems).
All images of histopathology were obtained with the Nuance multispectral
imaging system (CRI, Woburn, MA). This technology allows quantification of cell
types in defined regions of pathology. The entire region of the immunostained lungs
was captured using the 10x objective. Enumeration of normal lung, area percentages of
macrophages and lymphocytes, and total number of CD4+ and CD8+ cells was done
using the tissue and cell segmenting abilities of Inform software (CRI) as detailed by the
manufacturer’s instructions.
Lung cytokine expression. Total lung RNA was isolated by homogenizing lung
tissue in 1 ml of RNA-Bee (Tel-Test, Friendswood, TX), followed by addition of 0.1 ml
of chloroform (Sigma). The samples were mixed, incubated on ice for 15 min, and
centrifuged for 15 min at 13,000 rpm. The supernatants were removed and placed into
an equal volume of isopropanol for overnight precipitation. The samples were
centrifuged at 13,000 rpm for 15 min. The resulting RNA pellets were washed with 75%
ethanol and resuspended in water with 1 mM EDTA. cDNA was generated by mixing 2
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µg of RNA into first strand buffer (Invitrogen,), 2.5 mM dNTPs (Invitrogen), 0.1 M
DTT (Invitrogen), 80 U random hexamer (Roche Diagnostics, Mannheim, Germany),
and 20 U RNAsin (Promega, Madison, WI). The reaction mixture was heated to 70°C
for 5 min, followed by addition of 200 U SuperScript II RT (Invitrogen). The mixture
was heated to 42°C for 50 min, and then 70°C for 15 min to terminate the reaction.
Analysis of cDNA was performed using the Taqman assay. The sequences of
primers and probes (FAM reporter and BHQ-1 quencher) for the cytokines are shown in
Table 2.1. The reaction mixture contained 5 µl cDNA, 1X PCR buffer (5Prime, Fisher
Scientifics, Pittsburg, PA), 200 nM dNTPs (Invitrogen, Carlsbad, CA), 400 nM each for
the forward and reverse primer (Integrated DNA Technologies, San Diego, CA), 100 nM
probe (Biosearch Technologies, Novato, CA), 1x ROX reference dye (Invitrogen), and 1
U/50 µl Taq DNA polymerase (Fisher). The reaction was performed using the ABI
Sequence Detection System (Applied Biosciences, Carlsbad, CA) by heating for 1 min at
95 °C, and then 40 cycles of 95 °C for 12 seconds and 60 °C for 1 min. Data are
expressed as fold change expression relative to naive controls after normalization to βactin [202].
Preparation of lung digests and ELISpot analysis. Lung tissue from infected mice
was removed, minced, and incubated at 37°C with 30 µg/ml DNAse (Roche Diagnostics,
Mannheim, Germany) and 1 mg/ml type I collagenase (Worthington Biochemical
Corporation, Lakewood, NJ) for 60 min on a rotating shaker. The lung digests were
passed through a 40 µm filter (Fisher) followed by centrifugation at 1500 rmp. Red
blood cells were lysed with ACK lysing buffer (Lonza, Walkersville, MD). The cells
were washed 2 times with PBS and counted using a hemacytometer. One hundred µl of
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lung digests or splenocytes (2 x 105 cells) (see above) were examined for IFN-γ and IL17 producing cells (eBioscience, San Diego, CA) and CD4+ IFN-γ cells (R&D Systems,
Minneapolis, MN) according to the manufacturer’s instructions.
Recall response to MTB antigens. Recall responses by splenocytes to heat-killed
MTB was performed to evaluate lactoferrin modulation of the systemic immune
response to MTB. Spleens were harvested from infected mice at the times points
designated above. The tissues were minced using a glass homogenizer. Red blood cells
were lysed with ACK lysing buffer (Lonza), followed by washing twice with PBS.
After counting with a hemacytometer, cells were resuspended in Dulbecco’s modified
eagle’s medium (DMEM) (Sigma, St. Louis, MO) supplemented with 10% FBS, 0.01%
HEPES (Sigma), and 0.01% L-arginine (Sigma). Cells were plated into 24-well tissue
culture plates at a concentration of 2 x 106 cells/ml. Heat-killed MTB was added at a
MOI of 10:1, generated by autoclaving MTB suspended in 1xPBS at 121°C for 10 mins.
Subsets of cells were stimulated with 2 µg/ml conA or 10 ng/ml LPS as controls.
Supernatants were collected at 72 hours post-stimulation, filtered with a 2 µm filter, and
analyzed by ELISA for IL-17, IFN-γ, IL-10, IL-12p40, TNF-α, IL-6, and TGF-β (R&D
Systems).
Proliferation of MTB in broth and macrophage culture in the presence of
lactoferrin. MTB were grown in 7H9 broth alone, with 100 µg/ml lactoferrin, or with 1
mg/ml of lactoferrin. Bacteria were sonicated every 4 hours, the OD600 obtained, and
serial dilutions plated on 7H11 agar plates. The plates were incubated at 37 °C for 3 – 4
weeks.
For macrophage proliferation studies, the J774A.1 (ATCC TIB-67) were cultured
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in antibiotic-free DMEM with 2% FBS in 24-well tissue culture plates at a concentration
of 5 x 105 cells/ml. MTB Erdman were added at a MOI of 1:1. Subsets of cells were
given combinations of 10 ng/ml recombinant IFN-γ (Cell Sciences, Canton, MA), 100
µg/ml lactoferrin, and 1 mM of the NO synthetase inhibitor N-mono-methyl-arginine
(Sigma). The cells were lysed every 48 hours with 0.05% SDS, neutralized with 15%
bovine serum albumin (Sigma), and the lysates plated onto 7H11 agar plates. The cell
supernatants were also removed, filtered with a 0.2 µm filter and examined for IL-6,
TNF-α, IL-12p40, and TGF-β production by ELISA (R&D Systems). Production of NO
was assessed by the Griess reaction as previously described [246]. Briefly, 50 µl of the
culture supernatants were mixed with 50 µl of Griess reagent (1% sulfanilamide and
0.1% naphthyl-ethylenediamine dihydrochloride in 1 N HCL). The optical density at
550 nm was determined. NaNO2 was used to produce a standard curve.

Statistics. The data are shown as the mean ± SD. Two-way ANOVA was used to
determine the differences between groups by use of GraphPad Prism software. A pvalue of less than 0.05 was defined as statistically significant.

Results
Lactoferrin decreases bacterial burden in a mouse model of MTB infection
Acid-fast staining of lung tissue was performed by the Zhiel-Neelsen method
(Figure 4.1A). Control mice administered tap water had numerous acid-fast bacilli in the
lung at three weeks post-challenge with a highly virulent variant of MTB Erdman.
However, mice treated with lactoferrin had markedly fewer organisms visible on acid-
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LF at day 0

Figure 4.1. Decreased organ bacterial burden in lactoferrin treated mice. A.
Acid-fast staining in control mice three weeks post-infection demonstrates
numerous acid-fast bacilli. A similar region of histopathology in mice given
lactoferrin at day 0 shows markedly fewer bacteria. B. Mice treated with
lactoferrin at day 0 had significantly reduced bacterial burden in the lung at
weeks 2 and 3 post-challenge, accompanied by decreased CFUs in the liver
compared to mice given tap water. Mice started on lactoferrin at day 7 had
significantly decreased lung and liver CFUs at week 3. Data are presented as the
mean and SEM, n = 6 mice per group, per time point. *p < 0.05 with comparisons
to control mice.
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fast staining in regions with comparable histopathology. Bacterial CFUs in the lung,
liver, and spleen are shown in Figure 4.1B. Specifically, control mice administered tap
water had lung log10 CFUs of 2.5 ± 0.7 at week 1, 6.6 ± 0.9 at week 2, and 7.5 ± 0.3 at
week 3. In comparison, the mice treated with lactoferrin at the start of infection had
significantly fewer lung CFUs at week 2 (5.0 ± 1.4) and week 3 (6.4 ± 0.7). Mice
treated with lactoferrin beginning at day 7 after established infection at day 7 had
significantly reduced lung CFUs at week 3 (6.5 ± 0.4). Bacterial growth in the spleen
was not observed until week 2 and was not significantly different between the two
groups. Mice treated with lactoferrin at day 0 had significantly reduced liver CFUs at
weeks 1 and 3 compared to control mice. Mice given lactoferrin at day 7 had
significantly decreased liver bacterial loads only at week 3.

Lactoferrin reduces MTB induced lung immunopathology
Representative images of lung histopathology at three weeks post-challenge using
hematoxylin and eosin staining are shown in Figure 4.2. Control mice given tap water
have severe inflammation with nearly complete lung occlusion and large areas of
pulmonary edema (Table 4.1 and Figure 4.2A). High power images demonstrate a
predominance of macrophages, cellular debris, and tissue beginning to undergo necrosis
(Figure 4.2B). Few areas of lymphocytes were observed, with relatively few CD4+ and
CD8+ cells visualized with IHC (Table 4.1).
In contrast, mice treated with lactoferrin had significantly reduced lung occlusion
compared to control mice (Figure 4.2C and Table 4.1). There was significantly
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Figure 4.2. Histopathology in control (A & B) and lactoferrin treated
mice beginning at day 0 (C & D) at three weeks post-infection. A.
Control mice demonstrate nearly complete lung occlusion, 40X. B. High
power image from control mice shows large numbers of macrophages,
edema, and cellular debris, 400X. C. Mice treated with lactoferrin have
significantly less areas of inflammation and occlusion, 40X. D. Mice
treated with lactoferrin have clusters of lymphocytes, fewer areas of foamy
macrophages, and less edema, 400X. n = 6 mice per group.
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Table 4.1. Lactoferrin decreases lung immunopathology during MTB infection
Control
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decreased overall lung inflammation, less pulmonary edema and occluded vasculature,
and reduced areas of macrophages in mice started on lactoferrin at day 0 and day 7 postinfection. Clusters of lymphocytes were frequently observed (Figure 4.2D). The
majority of the lymphocytes were CD4+ cells; abundant CD8+ cells were observed as
well.

Lactoferrin enhances IFN-γ mediated killing of MTB and modulates cytokine production
in macrophage culture
Studies were undertaken to determine if lactoferrin has a direct effect on MTB
proliferation. The results of lactoferrin’s effect on MTB growth in broth culture are
shown in Figure 4.3A. A physiologic concentration of lactoferrin (100 µg/ml) did not
alter the growth of MTB in 7H9 broth using either the OD600 or CFUs. Only a very
high, non-physiologic concentration (1mg/ml) had a slight inhibitory effect on MTB
growth, possibly due to iron sequestration.
MTB proliferation with or without lactoferrin in macrophage culture was also
assessed (Figure 4.3B). Lactoferrin alone did not affect MTB growth in naive J774
cells. However, there was enhanced early killing when lactoferrin was used in
combination with IFN-γ. This effect is possibly mediated by NO, as macrophages given
the combination of lactoferrin and IFN-γ produced significantly more NO compared to
control and activated macrophages (Figure 4.4A). The addition of the NO synthetase
inhibitor N-mono-methyl-arginine abolished the enhanced MTB killing effect of
lactoferrin and IFN-γ (Figure 4.4B).
Lactoferrin modulated cytokine production from infected macrophages
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Figure 4.3. MTB proliferation in broth and macrophage culture in the
presence of lactoferrin. A. MTB were grown in 7H9 broth alone, with 100
µg/ml lactoferrin, or 1 mg/ml lactoferrin. The OD600 values and bacterial CFUs
both show that physiologic concentrations of lactoferrin (100 µg/ml) do not alter
MTB growth. Only very high, non-physiologic concentrations of lactoferrin
have a slight impact of MTB growth. B. J774 macrophages were cultured in
DMEM, infected with MTB at a MOI of 1:1, and treated with various
combinations of lactoferrin and IFN-γ. Lactoferrin alone did not impact MTB
proliferation in macrophages. However, there was enhanced early killing by the
combination of lactoferrin and IFN-γ.
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A.

B.

Figure 4.4. Lactoferrin enhances IFN-γ mediated NO production.
A. NO production was measured in the supernatants from infected J774
cells using the Griess reaction. Macrophages treated with the
combination of lactoferrin and IFN-γ had markedly enhanced NO
production. * p < 0.05, with comparison to control macrophages. ** p
< 0.05 with comparison to control macrophages activated with IFN-γ.
B. Macrophages were treated with 1mM of the nitric oxide synthase
inhibitor n-monomethyl-l-arginine (NMMA) with various
combinations of 100 µg/ml lactoferrin (LF) and 10 ng/ml IFN-γ.
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Figure 4.5. Lactoferrin modulates cytokine production by
infected macrophages. J774 cells were cultured in DMEM,
infected with MTB at a MOI of 1:1, and treated with various
combinations of lactoferrin and IFN-γ. Supernatants were collected
at the indicated time points, filtered with a 0.2 µm filter, and
analyzed for TNF-α, IL-6, IL-12p40, and TGF-β by ELISA. * p <
0.05 with comparisons to control macrophages.
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(Figure 4.5). There was significantly increased TNF-α production when lactoferrin was
added to macrophages activated with IFN-γ. Of potential importance, lactoferrin
significantly increased IL-12p40 production, a cytokine of critical importance for the
induction of Th1 responses [162, 163]. TGF-β synthesis was also significantly
increased, a cytokine that has a number of regulatory functions [247].

Lactoferrin modulates lung cytokine expression in MTB infected mice
Lung cytokine expression of TNF-α, IL-6, IL-12p40, TGF-β, IL-10, IFN-γ, and
IL-17 was evaluated by Taqman qPCR (Figures 4.6 and 4.7). Control mice increased
expression of all cytokines over the three-week time course, with the exception of IL12p40 expression that peaked at week 2. Lactoferrin administered both at day 0 and day
7 post-challenge significantly decreased expression of the proinflammatory cytokine IL6. IL-10, a cytokine with inhibitory actions on cell-mediated immunity, was also
decreased by lactoferrin treatment. There was a non-significant trend towards increased
IFN-γ expression in the lactoferrin treated mice. IL-17 expression was significantly
increased by lactoferrin treatment. There were no significant differences in lung
expression of TNF-α, IL-12p40, or TGF-β between control and lactoferrin treated mice.

Increased Th1 and IL-17 producing cells in the lung and spleens of lactoferrin treated
mice
Lung and spleen homogenates were examined for IFN-γ, and for CD4+ IFN-γ
producing cells by ELISpot analysis (Figure 4.8). The levels of IFN-γ producing cells in
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Figure 4.6. Lung expression of proinflammatory mediators in MTBinfected mice treated with lactoferrin. Expression of TNF-α, IL-6, and
IL-12p40 mRNA was quantified in the lung in mice challenged with MTB
and treated with or without lactoferrin. Data are expressed as fold change
relative to naïve mice after normalization to β-actin. Data are presented as
the mean with SD, n = 6 mice per group, per time point. * p < 0.05,
comparisons are made to control mice.
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Figure 4.7. Lung expression of cytokines in MTB-infected mice
treated with lactoferrin. Expression of TGF-β, IL-10, IFN-γ, and IL17 was quantified in the lung in mice challenged with MTB and treated
with lactoferrin. Data are expressed as fold change relative to naïve
mice after normalization to β-actin. Data are presented as the mean with
SD, n = 6 mice per group, per time point. * p < 0.05, with comparisons
to control mice.
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Figure 4.8. IFN-γ and CD4+ IFN-γ producing cells in the lung and
spleen in control and lactoferrin treated mice. Lung and spleen
homogenates were incubated with heat-killed MTB for 48 hours. Cells
producing IFN-γ and CD4+ IFN-γ+ cells were enumerated by ELISpot
analysis. Comparisons made to control mice, n = 4 mice per group per
time point. * p < 0.05
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the lung increased over the three-week time course in all groups examined. The number
of lung IFN-γ synthesizing cells became significantly greater at week 3 in both
lactoferrin treatment groups compared to control mice. The absolute numbers of IFN-γ
producing cells in the spleen peaked at week 2 in all treatment groups. Splenocytes had
a higher number of IFN-γ producing cells at week 2 post-MTB challenge in the
lactoferrin treated mice compared to control mice. To determine if these IFN-γ
synthesizing cells were Th1 cells, the lung and spleen digests were plated onto an
ELISpot plate specific for CD4+ IFN-γ cells. The numbers of CD4+ IFN-γ+ cells in the
lungs were increased at week 3 in all groups examined, but significantly greater in the
lactoferrin treatment groups. CD4+ IFN-γ+ cells in the spleen were not significantly
different between the groups.
IL-17 producing cells in the lung and spleen were also evaluated (Figure 4.9). The
total number of IL-17+ cells increased in the lungs over the three-week observation
period. There were significantly increased levels of IL-17 producing cells in the lung at
week 2 in the lactoferrin treated mice. The spleen had relatively few IL-17 producing
cells, with no significant differences between the groups.

MTB-specific responses by splenocytes are altered by lactoferrin treatment
Splenocytes from control and lactoferrin treated mice were isolated and stimulated
with heat-killed MTB for 72 hours. Supernatant TNF-α, IL-6, IL-12p40, TGF-β, IL-10,
IFN-γ, and IL-17 levels are shown in Figures 4.10 and 4.11. Splenocytes from both
lactoferrin treatment groups had significantly elevated IL-12p40 at week 2 and IFN-γ at
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Figure 4.9. IL-17 producing cells in the lung and spleen in control
and lactoferrin treated mice. Lung and spleen homogenates were
incubated with heat-killed MTB for 48 hours. IL-17 producing cells
were enumerated by ELISpot analysis. Comparisons are made to control
mice, n = 4 mice per group per time point. * p < 0.05
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Figure 4.10. Specific protein production of proinflammatory
mediators from control and lactoferrin treated mice. Splenocytes
from control and lactoferrin treated mice were stimulated with heat-kill
MTB for 72 hours. TNF-α, IL-6, and IL-12p40 were measured in the
supernatants by ELISA. Comparisons are made to control mice. Data are
presented as the mean with SD, n = 4 mice per group per time point. * p <
0.05
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Figure 4.11. Specific protein production of cytokines from control and
lactoferrin treated mice. Splenocytes from control and lactoferrin treated
mice were stimulated with heat-kill MTB for 72 hours. TGF-β, IL-10,
IFN-γ, and IL-17 were measured in the supernatants by ELISA.
Comparisons are made to control mice. Data are presented as the mean
with SD, n = 4 mice per group per time point. * p < 0.05
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week 3. The mice given lactoferrin at day 7 after infection had increased TNF-α and IL10 at week 3, and increased IFN-γ recall response at week 2. Both lactoferrin treatment
groups had decreased IL-17 splenocyte synthesis at week 2. There were no differences
in splenocyte synthesis of IL-6 or TGF-β in response to heat-killed MTB.

Discussion
TB continues to be a major cause of morbidity and mortality due to infectious
diseases. Treatment of this disease requires 6 – 9 months of anti-TB chemotherapy that
is difficult to administer in the regions of the world that have the highest burden of TB
cases. Thus, there is a considerable need to develop novel agents for the treatment of TB
both to shorten the treatment time and combat the emergence of drug resistant
organisms. Increasing evidence suggests that immune modulating therapies that target
granulomas and enhance protective immune responses may be useful as adjunct
therapeutics for the treatment of TB [15].
Lactoferrin treated mice demonstrated a decrease in lung bacterial CFUs and a
reduction in bacterial dissemination to the liver. These favorable effects were evident
even when the mice were treated one week post-infection, indicating that lactoferrin has
the potential as a novel agent for the treatment of TB. This decrease in bacterial burden
is not likely due to a direct effect of lactoferrin on MTB because physiologic
concentrations of lactoferrin did not alter MTB proliferation in either broth or
macrophage culture. Thus, we hypothesize that the mechanism of bacterial reduction is
due to immune modulation. Indeed, mice treated with lactoferrin had higher numbers of
Th1 cells in the lung at three weeks after infection. Lactoferrin has been shown to
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increase cell-mediated immune responses in a number of infectious disease models
[140]. Enhancement of antigen presenting cell activity is one potential mechanism by
which lactoferrin may promote Th1 responses. Lactoferrin increased expression of
MHC II and the CD86:CD80 ratio in BCG-infected macrophages and dendritic cells, and
resulted in increased production of IFN-γ from overlaid CD3+ and CD4+ cells compared
to cells cultured without lactoferrin [155-157]. Lactoferrin may also enhance Th1
responses by modulation of antigen presenting cell cytokine production. Lactoferrin was
demonstrated to increase production of IL-12 in a number of studies [155-157, 164,
228], including the data presented here. IL-12 is an essential cytokine for induction of
IFN-γ from naive T-cells and enhancing production from mature Th1 cells [162, 163].
Furthermore, lactoferrin appeared to enhance IFN-γ mediated bacterial killing in
macrophage culture; this effect is possibly due to enhancement of NO production. Other
studies have reported increased NO production by lactoferrin, both in macrophage
culture and in vivo [231, 248]. IFN-γ induced NO synthesis by macrophages is
considered a crucial antimycobacterial activity [249]. Thus, we hypothesize that a major
mechanism of lactoferrin’s favorable effect during MTB infection is the generation of
IFN-γ producing cells; IFN-γ in turn acts synergistically with lactoferrin to enhance
macrophage killing of MTB, possibly through NO production.
Lactoferrin increased IL-17 producing cells in the lung in addition to
enhancement of IFN-γ mediated responses. To our knowledge, this is the first report of
lactoferrin modulation of IL-17 responses. Several studies suggest that IL-17
synthesizing cells may play an important role in MTB host defense [64, 65, 241]. Early
enhancement of IL-17 responses by use of an IL-23 producing adenovirus during MTB
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infection resulted in decreased bacterial burden and reduced lung pathology [67]. Thus,
an early increase in IL-17 responses in the lactoferrin treated mice may have contributed
to the reduction in bacterial CFUs and lung histopathology. The mechanisms by which
IL-17 may be protective during MTB challenge include augmentation of bacterial killing
by enhancement of IFN-γ responses that activate macrophages, direct stimulation of
phagocytic cells, recruitment of neutrophils, and increasing expression of antimicrobial
peptides that have activity against MTB [67, 250].
Mice treated with lactoferrin had a marked reduction in lung immunopathology
in addition to a decrease in bacterial CFUs. Modulation of MTB-induced inflammatory
pathology has been proposed as a mechanism to decrease the treatment time for TB [15],
an approach successfully used in animal studies and human clinical trials. For example,
the TNF-α reducer thalidomide used in combination with anti-TB antibiotics reduced
mortality, brain pathology, and leukocytosis in a rabbit model of TB meningitis
compared to anti-TB chemotherapy alone [251]. A clinical trial exploring the
combination of etanercept, a soluble TNF-α receptor, with TB antibiotics in patients coinfected with HIV and TB reported increased bacterial clearance and improved chestrays with the combination therapy [135]. A second clinical trial in individuals with HIV
and TB demonstrated a higher rate of sputum culture conversion when high dose
prednisolone was used as the immunomodulator in conjunction with TB antimicrobial
chemotherapy [136]. In addition to an overall reduction in lung pathology, lactoferrintreated mice had a decreased percentage of macrophages, an increased percentage of
lymphocytes, and increased numbers of CD4+ and CD8+ cells, suggesting an increase in
immune cells with protective effects during MTB infection.
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In light of the increased emergence of drug resistant organisms and the
increasing incidence of TB, it is essential to develop new agents for the treatment of TB.
It is noteworthy that lactoferrin reduced bacterial burden, accompanied by an increase in
certain proinflammatory responses while decreasing overall lung immunopathology.
Lactoferrin has a number of advantages over the current immunomodulators in use
because it does not suppress the immune system and has a proven safety record in a
number of animal models and human clinical trials [138, 139, 235, 236]. These
investigations indicate that lactoferrin has potential as a novel therapeutic for the
treatment of TB.
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Chapter Five
General Discussion
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A major focus of this thesis centered on investigations into the molecular control
of the granulomatous response to mycobacterial cord factor trehalose-6’6-dimycolate
(TDM). The granuloma is the histopathologic hallmark of Mycobacterium tuberculosis
(MTB) infection. The tuberculosis (TB) bacilli are likely recognized by alveolar
macrophages following inhalation of the organism [17]. These macrophages secrete
cytokines and chemokines that recruit monocytes from systemic circulation and form the
innate granuloma. At some point after infection, a dendritic cell becomes infected or
processes MTB antigen and migrates to the draining lymph node of the lung. Dendritic
cell presentation of MTB antigen to naive T-cells generates adaptive immune responses.
Antigen-specific T-cells migrate to the lung and surround infected macrophages,
generating mature granulomas [17].
Granuloma formation is often considered a “double-edged sword” in the host
defense against MTB [15]. Granuloma formation is clearly needed to prevent
uncontrolled infection and bacterial dissemination, as demonstrated in both animal and
studies where factors essential for granuloma generation and maintenance are
dysregulated [190, 204, 207]. However, there is increasing evidence that MTB possess
certain factors that specifically drive granuloma formation and tissue remodeling that
results in physical sequestration of the bacilli from effector immune cells capable of
killing the organism [15]. Specifically, MTB has been shown to directly interfere with
intracellular signaling to drive granuloma formation. A MTB mutant lacking the
adenylate cyclase Rv0386 was characterized by reduced cAMP after infection,
accompanied by decreased protein kinase A and CREB activation, and ultimately
decreased TNF-α synthesis by infected macrophages [104]. The mutant MTB had poor
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survival in a mouse infection model and decreased lung pathology. MTB also possess
mycolic acids, such as trehalose dimycolate, that have been shown to drive granuloma
formation [13, 116, 118]. Thus, an understanding of the immunological factors that
drive granuloma formation may lead to novel targets for the treatment of tuberculosis. A
portion of this thesis specifically explores the role of TNF-α, complement factor C5a,
and IL-6 in the generation and maintenance of TDM induced granulomas.
The TDM model of granuloma formation mimics certain aspects of MTB
induced immunopathology and is ideal for studying the immunologic factors necessary
for early granuloma formation [13, 116, 118, 119, 130]. The investigations presented in
this thesis demonstrate that TNF-α is a key cytokine in mycobacterial TDM induced
granulomas. TNF-α deficient mice challenged with intravenous TDM prepared in
emulsion form failed to generate a histological response to TDM, accompanied by an
absence of proinflammatory mediators and chemokines. Macrophages are the innate cell
type that responds to TDM [122] and are likely the source of TNF-α during the initial
immune response to MTB [252]. TNF-α possibly acts by inducing chemokines during
early infection that facilitate recruitment of other immune system cells [191]. Studies
performed on animal models of MTB infection indicate that TNF-α is clearly involved
in the maintenance of established granulomas because treatment with a TNF-α
neutralizing antibody disrupts chronic granulomas [190], but this phenomenon could not
be evaluated in the TDM granuloma model. Use of TNF-α neutralizing therapy in
patients latently infected with MTB resulted in reactivation of latent infection, often
accompanied by extrapulmonary disease [204]. Inhibition of TNF-α during TB
chemotherapy has been proposed as a novel therapeutic strategy because neutralization
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of TNF-α has been shown to convert MTB from a state of non-replicating persistence to
active replication, thus making the bacteria susceptible to antibiotics [15]. This
approach was successful in both an animal model and a human clinical trial [135, 251],
indicating that TNF-α may be a useful target employed during antimycobacterial
chemotherapy.
The studies in this thesis also demonstrate that complement factor C5a plays a
role in the generation of cohesive granulomas to TDM. C5a -/- mice developed severe
pathology accompanied by reduced early synthesis of proinflammatory mediators and an
absence of IL-12. Complement C5a is a potent anaphylatoxin that recruits cells to the
sites of active inflammation [87]. Thus, it is intriguing that deficiency of a chemotactic
factor resulted in increased influx of cells that produced less inflammatory cytokines.
C5a is necessary for NFκB activation, an expression regulator for a variety of
inflammatory mediators, thus possibly accounting for the delayed expression of
proinflammatory mediators [215]. Furthermore, C5a induces macrophage adhesion
molecule expression [216, 217], possibly accounting for the inability of C5a-/- mice to
form cohesive cellular aggregates. The inability of complement deficient animals to
produce IL-12 has been documented in a number of other investigation, but a precise
mechanism has yet to be defined [88]. A number of studies have indicated that the
decreased IL-12 production by complement deficient animals results in defective cellmediated immunity [92, 212, 253]. However, studies in humans have not demonstrated
an increased susceptibility to TB in patients deficient in complement components; in
fact, it has been suggested that such patients may be less susceptible to TB because of
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reduced opsonization and phagocytosis [254]. Therefore, the role of the complement
system in TB infection and as a therapeutic target remains to be determined.
IL-6 also appears to play a role in TDM induced granulomas. Mice deficient in
this cytokine initially formed granulomas, but failed to maintain them and had severe,
edematous inflammation. The IL-6 -/- mice had decreased early production of
proinflammatory mediators, similar to the complement deficient mice. An investigation
by Clahsen and Schaper [255] demonstrated that IL-6 promoted activation of β1-integrin
and cellular migration across endothelial cells, suggesting that IL-6 has chemokine-like
properties. It is hypothesized that IL-6 from macrophages may thus be needed to
maintain a coordinated response to mycobacterial antigens. Additionally, a recent
investigation demonstrated that IL-6 is necessary for regulating local concentrations of
glucocorticoids that modulate pathological responses [219]. The TDM model used in
these experiments explores early, innate immune responses. Thus, the role of IL-6 in
chronic TB infection cannot be determined from these studies. Long-term studies of the
role of IL-6 using MTB infection have generated mixed results. An intravenous
challenge of 106 MTB was lethal for IL-6 -/- mice in one study [107]; however, a low
dose aerosol challenge of IL-6 deficient mice in a different investigation had reduced
IFN-γ production but ultimately contained the infection [105]. The role of IL-6 in
human TB infection is less clear. To date, there have been no studies that link IL-6
polymorphisms or disruption of IL-6 to TB susceptibility [256]. Therefore, the role of
IL-6 as a therapeutic target for TB treatment remains to be clarified.
The overall hypothesis from our studies on the cytokine mechanisms of TDMinduced granuloma formation is that TNF-α is essential for the initiation of an
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inflammatory response to TDM, possibly by inducing chemokines needed to recruit cells
to the lungs. Once a response has been initiated, complement C5a and IL-6 recruit cells
that produce regulating cytokines and upregulate integrin that allow cells to form
organized, cohesive structures. Such studies may provide insight on the implications of
using cytokine inhibitors to treat patients with chronic inflammatory disorders who may
have latent TB disease as well as provide targets for the treatment of TB.
Granulomas are clearly essential in the prevention of uncontrolled bacterial
proliferation and dissemination. However, it is hypothesized that modulation of
granuloma structure may be a novel target for the treatment of TB [15]. MTB
sequestered within granulomas enter a state of non-replicating persistence characterized
by absent bacterial division and the use of altered biosynthetic pathways [131, 132], thus
rendering the bacteria relatively resistant to the action of antibiotics. The physical
structure of the TB granuloma is such that killer lymphocytes capable of lysing infected
cells are physically separated from the infected cells by a layer of fibrosis [17]. Finally,
reducing the inflammatory pathology induced by MTB may enhance antibiotic
penetration into tissues. Reduction of pathology has led to favorable results in both
animal and human studies [135, 136, 251]. Therefore, studies were undertaken to
develop a therapeutic to reduce the pathological response to MTB and its antigens.
Lactoferrin was selected the candidate immune modulator for these studies
because it has been shown to reduce immune mediated tissue destruction in a variety of
inflammatory and infectious disease models. For example, lactoferrin added to the BCG
vaccine as an adjuvant resulted in both increased protection following challenge with
virulent MTB and decreased lung occlusion [232]. Additionally, mice injected with LPS
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and treated with lactoferrin had decreased mortality and reduced gut tissue destruction
[183]. Therefore, studies were conducted to determine if lactoferrin is able to modulate
the immune response to mycobacterial antigens using TDM.
Macrophages were first stimulated with TDM-coated beads and lactoferrin added
to the culture media; lactoferrin treatment of the macrophages resulted in globally
reduced proinflammatory cytokine production. Mice challenged intravenously with
TDM and treated with 24 hours later had significantly fewer and smaller granulomas at
the peak of the granulomatous response. Overall, proinflammatory cytokine production
in the lungs of TDM-challenged mice was not significantly altered by lactoferrin;
however, TGF-β and IL-10, cytokines that can have anti-inflammatory functions, were
increased in lactoferrin treated mice. When macrophages were infected with MTB and
treated with lactoferrin, production of certain proinflammatory cytokines were increased.
It is hypothesized that lactoferrin modulated macrophage cytokine production in vivo to
reduce the histopathological response to TDM. However, it is intriguing that different
cytokine responses were obtained when lactoferrin was added to macrophages
stimulated with TDM-coated microspheres, mice challenged with TDM, and
macrophages infected with MTB. Lactoferrin is known to have different effects
depending on the model system, the inflammatory stimulus, and the immune status of
the host [140]. For example, lactoferrin treated macrophages stimulated with a low dose
of LPS had increased production of proinflammatory cytokines compared to untreated
cells [175]. However, macrophages given higher doses of LPS had reduced
proinflammatory cytokine production when lactoferrin was added to the culture media.
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This unique property of lactoferrin makes it an ideal candidate immunomodulator for a
number of inflammatory and infectious diseases.
The differing cytokine production when macrophages are given isolated TDM
and live mycobacteria suggested that in vivo infection with MTB would likely give
different results than those obtained from the TDM model. Additionally, the TDM
model used in these studies only allows exploration of innate responses. Cell-mediated
immunity is critical to the control of TB infection, which cannot be evaluated in the twoweek TDM model. Furthermore, the alteration of granuloma structure and production of
cytokines with anti-inflammatory properties may result in enhanced bacterial
dissemination from the lung [131], a phenomenon that cannot be evaluated using the
TDM model. Therefore, mice were aerosol challenged with a low dose of MTB strain
Erdman and treated with lactoferrin by adding it to the drinking water. We found that
mice treated with lactoferrin at the start of infection or one week after infection had
decreased organ bacterial burden. Furthermore, lactoferrin treated mice had decreased
lung histopathology, fewer areas of foamy macrophages, and increased numbers of
lymphocytes. The fact that lactoferrin had a favorable effect even when given after
established infection indicates that lactoferrin has the potential to be a novel therapeutic
for the treatment of TB.
The hypothesized mechanism of lactoferrin-mediated reduction in bacterial
burden is the early induction of Th1 immune responses. Th1 cells produce IFN-γ, which
in turn acts synergistically with lactoferrin to augment nitric oxide mediated killing of
MTB by macrophages (Figure 5.1). A number of other investigations have reported that
lactoferrin increases Th1 responses. For example, lactoferrin administered orally
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Figure 5.1. Hypothesized mechanism for the reduction in MTB bacterial
burden by lactoferrin treatment. Innate antigen presenting cells present
MTB antigen to naive T-cells on MHC II. Lactoferrin augments the induction
of Th1 cells by increasing IL-12 production, as well as increasing expression
of MHC II and the costimulatory molecules CD40 and CD86. IFN-γ
production by Th1 cells acts synergistically with lactoferrin to promote MTB
killing by macrophages in a nitric oxide dependent manner.
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increased Th1 responses, indicated by increased IFN-γ production, in both naive and
tumor-harboring mice [173, 174]. Transgenic mice expressing human lactoferrin and
infected with Staphylococcus aureus had increased IFN-γ and TNF-α, along with
decreased IL-10 and IL-5 [172]. The possible mechanism by which lactoferrin increases
Th1 responses is enhancement of innate immune cell antigen presentation and increased
production of IL-12 [140]. While lactoferrin increased Th1 responses in the studies
presented here, others have reported that lactoferrin can increase Th2 responses
depending on the model system. For example, lactoferrin increased IL-10 and decreased
IFN-γ in an infection model of Toxoplasma gondii, indicating the enhancement of Th2
responses [177]. The precise mechanisms by which lactoferrin promotes Th1 versus
Th2 responses is unknown; however, this ability of lactoferrin gives it the potential to be
beneficial in a number of disease states.
Lactoferrin treatment also increased the numbers of IL-17 producing cells in the
lungs of MTB infected mice. To our knowledge, this is the first report of lactoferrin
affecting levels of IL-17+ cells. New evidence suggests that IL-17 producing cells play
an important role in the host defense against MTB [64, 65, 241]. Of importance to these
studies, early enhancement of IL-17 responses by administration of an IL-23 producing
adenovirus during infection with MTB reduced lung bacterial burden and pathology
[67]. Thus, the early appearance of IL-17 producing cells in the lactoferrin treated mice
may have contributed to the reduced pathology and bacterial burden. Potential
mechanisms by which IL-17 may be protective during MTB infection include
enhancement of IFN-γ responses that activate macrophages, neutrophil recruitment,
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stimulation of phagocytic cells, and increasing expression of antimicrobial peptides with
activity against MTB [67, 250].
While a number of receptors for lactoferrin have been reported [141], the precise
intracellular signaling mechanisms induced after activation by lactoferrin remain
undefined. A 105-kDa lactoferrin receptor is found on platelets and lymphocytes and
possibly initiates signaling cascades [166, 257]. Lactoferrin was shown to bind surface
nucleolin, followed by endocytosis, and translocation of the lactoferrin/nucleolin
complex to the nucleus [258]. Other lactoferrin receptors are the low-density lipoprotein
receptor related proteins (LRPs) that are found on a number of cell types including
macrophages [141]. Finally, an intestinal receptor that induces lactoferrin endocytosis is
hypothesized to promote IL-18 synthesis and increase in systemic Th1 responses [259].
How lactoferrin promotes different immune responses is likely dependent on the model
system under investigation.
The ability of lactoferrin to have a favorable effect during MTB infection when it
is administered orally increases its appeal as a therapeutic, especially in drug-resistant
infections that require the administration of injectable medications. However, it is not
clear if lactoferrin’s effects were mediated by modulation of systemic immune responses
or local action at the lung. The decreased CD4+IFN-γ+ and IL-17+ cells in the spleen
compared to the lung suggest that lactoferrin had different local and systemic responses.
Lactoferrin undergoes partial digestion in the gastrointestinal tract to produce peptides,
such as lactoferricin, that have antimicrobial effects [260]. The effects of specific
lactoferrin peptides on MTB growth and immune modulation during MTB infection are
currently unknown. However, an investigation in humans reported that gastric survival
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of lactoferrin is at least 60% [261]. Studies in mice demonstrate that intact lactoferrin
accumulates in a number of organs shortly after oral administration [262]. A study using
a peptide of human lactoferrin showed that it accumulates at sites of active inflammation
in a mouse model of MRSA infection [263]. Thus, orally administered lactoferrin has
the potential to modulate infection and inflammation in specific tissues.
Further increasing the appeal of lactoferrin is its favorable safety profile in a
number of animal and clinical studies. A major concern over the use of novel agents in
the treatment of TB is that the long use required for treatment may result in toxicity.
F344/DuCrj rats given bovine lactoferrin in their diet for 40 weeks had no clinical signs
of toxicity and had significantly lower liver transaminases, blood urea nitrogen, and
triglyceride levels compared to control rats [138]. A phase 2 clinical trial was conducted
in patients with disseminated renal cell carcinoma who were given a recombinant form
of human lactoferrin for 12 weeks reported good tolerability and no renal, hematologic,
or hepatic toxicities [137]. No major toxicities were reported in a 12 week trial
evaluating the impact of bovine lactoferrin on patients with chronic hepatitis C [139].
Thus, lactoferrin represents a natural molecule that is well suited for clinical use.

Future Directions
TB remains a major public health problem, accounting for approximately 2
million deaths each year [1]. The studies presented in this thesis indicate that lactoferrin
has the potential to be a novel therapeutic in the treatment of TB. However, TB
treatment requires the use of a combination of at least four drugs [2]. It is essential to
confirm that lactoferrin still has a favorable effect when used in a combination drug
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regimen. It is theoretically possible that lactoferrin may antagonize the action of a
specific antimycobacterial antibiotic. Furthermore, such studies will determine if
lactoferrin can be used in combination with standard TB drugs to generate novel drug
regimens that will allow for shortening the time needed to treat TB.
To our knowledge, these studies are the first to report that lactoferrin increases
production of IL-17. Future studies can be performed to further characterize the
importance of these responses. For example, IL-17 knock-out mice (currently not
commercially available) can be infected with MTB and treated with lactoferrin to
determine if lactoferrin still has a favorable effect in the absence of IL-17. Alternatively,
wild-type mice can be treated with a neutralizing IL-17 antibody, but such experiments
are extremely expensive.
Additionally, it is not known if lactoferrin acted systemically or locally in the
lungs when either TDM-challenged or MTB-infected mice were treated with lactoferrin.
Studies can be undertaken to label lactoferrin and determine its distribution in MTB
infected mice. Additionally, it is possible that lactoferrin peptides generated in the
digestive tract of treated animals may be responsible for some of the effects observed.
Thus, peptides of lactoferrin can be generated and tested for immune modulating activity
and therapeutic potential during MTB treatment.
Finally, these experiments explored the utility of lactoferrin in an acute model of
MTB. Human patients are likely to present for treatment with chronic lesions. It is
unclear at this time if administration of lactoferrin to individuals with on-going chronic
disease will alter pathology. Experiments can be performed to determine if lactoferrin
still has a favorable effect when administered to animals with established chronic
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infection. However, humans with active TB often have cavitary lesions. Unfortunately,
the animal models that adequately replicate the cavitary lesions that are found in human
post-primary TB patients are not completely standardized [13]; it would be premature to
investigate lactoferrin effects in these model systems until this obstacle if overcome.
In summary, these studies provide insights into the cytokine mechanisms by
which mycobacterial antigens induce granulomas. The lung immunopathology induced
by trehalose-6’6-dimycolate can decreased by lactoferrin, possibly by modulation of
macrophage cytokine production. Finally, lactoferrin has a number of favorable effects
during MTB infection including reduction of organ bacterial burden and lung
inflammation. The hypothesized mechanism by which lactoferrin decreases bacterial
CFUs is by increasing Th1 responses and increased IFN-γ mediated killing by
macrophages. Thus, lactoferrin has the potential as a novel therapeutic for TB treatment.
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